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ABSTRACT 
 
 
Notch deregulation occurs in several solid and hematopoietic tumors. Recently, Notch 
receptor oncogenic role has been shown to be critical in multiple myeloma (MM) which 
frequently displays over-expression of the Notch ligand, Jagged2. MM is a malignant 
disorder in which the tumor microenvironment plays a critical role: in this contest, Ig-
secreting plasma cells accumulate in the bone marrow where they interacts with stroma and 
BM cells. 
The cross-talk between MM cells and BM milieu activates signaling such as chemokines 
and their receptors (CRs) pathways that mediate growth, survival and migration of MM 
cells, cell-adhesion-mediated drug resistance (CAM-DR) and finally bone lesions trough 
hyper-stimulation of osteoclasts (OCLs) activity. 
In our study we took advantage of a panel of MM and bone marrow stromal (BMSC) cell 
lines and investigated the effects of the Notch signaling withdrawal on MM cell and 
several chemokine systems. Inhibition of Notch activity, obtained by treatment with 
gamma-secretase inhibitor (GSI) or Jagged 1 and 2 knock-down indicated that Notch 
down-regulation hampers MM cell growth, arresting cell cycle progression and 
inducing increase of apoptosis. 
Moreover the effects of Notch inhibition on the expression of a number of CRs and 
correspondent ligands which display a relevant role in MM were investigated: mRNA and 
protein expression of CXCR4 and SDF-1 were under Notch control. Functional 
consequences of Notch inhibition were analyzed: GSI XII inhibits SDF1-dependent 
chemotaxis and proliferation of MM cells. 
Afterwards, the role of Notch in the MM cells relationship with the BM microenvironment 
was investigated trough co-culture assays. Our results show that Notch is able to control the 
cross-talk between MM and BMSCs trough the modulation of SDF-1 and other soluble 
factors produced by stroma, initiating in this way, a surviving loop. 
Thus, Notch pathway is able to modulate the MM cell proliferation, apoptosis and 
migration by directly deregulating the CXCR4/SDF-1 axis activity and the cross-talk 
between MM cells and BMSCs. 
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INTRODUCTION 
 
 
1. THE NOTCH SIGNALING PATHWAY 
 
Notch genes encode evolutionarily conserved transmembrane bound receptors (Fleming, 
1998). Notch was  initially identified and studied for yielding a ‘notched’ wing phenotype 
in the fruit fly Drosophila Melanogaster (Dexter, 1914; Morgan, 1917) due to a 
haploinsufficency of the Notch gene. The precise numbers of Notch paralogues differ 
between specie: there are two Notch receptors in Caenorhabditis elegans (LIN-12 and GLP-
1), one in Drosophila melanogaster (Notch) and four Notch receptors in mammals 
(Notch1–4) located on chromosomes 9q34, 1p13-p11, 19p13.2-p13.1, and 6p21.3, 
respectively (Yeh, 2003) which display both redundant and uniques functions. The pathway 
has since been implicated in development of several different tissues and organisms. The 
Notch pathway regulates cell fate decisions during embryonic development by facilitating 
short-range signalling between neighbouring cells that are in physical contact; in mammals, 
Notch plays a critical role in the regulation of neurogenesis, gliogenesis, myogenesis, 
vasculogenesis, hematopoiesis and development of the epidermis. in a context-dependent 
manner, in fact Notch signalling coordinates a wide range of fundamental processes and 
cellular programs including proliferation, apoptosis, migration, growth, and differentiation 
(Artavanis-Tsakonas, 1999; Greenwald, 1998; Kopan, 1996; Kopan, 2009). Because of its 
broad involvement in all these process, mutations or deregulation of Notch receptors and/or 
ligands are associated with the onset of various diseases, including solid cancers (breast, 
ovarian, prostate, cervical, skin, pancreas and liver cancer, neuroblastoma), T-cell 
leukemia, and multiple myeloma . 
 
1.1 NOTCH RECEPTORS 
Notch receptors are single pass type I transmembrane proteins. The mature form of Notch 
on the cell surface is a large heterodimer, held together by non-covalent calcium-dependent 
interactions through the heterodimerization domain (HD). The structure of the receptor (fig. 
1.1.1) comprises three domains, in which different regions are associated with different 
functions (Chillakuri, 2012): 
An extracellular domain (NECD), which contains: 
• At the N-terminus, a variable number of tandem Epidermal Growth Factor (EGF)-like 
repeats (ELR) in mammals (36 in Notch-1 and Notch-2; 34 in Notch-3, and 29 in 
Notch-4) mediate positive interactions with ligand presented by neighboring cells 
(repeats 11–12) and also mediate inhibitory interactions with ligand co-expressed in the 
same cell (repeats 24–29) (Rebay, 1991). Many EGF repeats bind calcium (cbEGF-like 
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domain), which plays an important role in determining the folding structure and affinity 
of Notch to its ligands (Wharton, 1985; Rand, 2000). The EGF-like repeats are site of 
post-translational modifications (including fucosylation and glycosylation) which 
influence the maturation of Notch and its binding to the ligands (Okajima, 2003).  
• three cysteine-rich Lin12-Notch repeats (LNR), which is critical to avoid receptor 
activation in absence of the ligand (Wharton, 1985); 
• a heterodimerization domain (HD), a C-terminal hydrophobic region of 100 aminoacids, 
containing two cysteine, fundamental for the heterodimerization between extracellular 
and intracellular domains and required for maintaining the receptor in inactive 
conformation; together, the LNR repeats and the HD domain form the negative 
regulatory region (NRR), adjacent to the cell membrane. This region prevents ligand-
independent activation of the Notch receptor by concealing and protecting the S2 
cleavage site from metalloproteases (Sanchez-Irizarry, 2004) 
A transmembrane domain (TMD), which contains: 
• a single transmembrane region, terminated by a “stop translocation” signal comprised of 
3-4Arg/Lys residues, which is the substrate for regulated intramembrane proteolysis; 
An intracellular domain (NICD), which contains: 
• a high affinity binding module called RAM (RBPjk association module) domain of 12-
20 aminoacids (Tamura, 1995); 
• seven repeats of CDC10/ankyrin (ANK domain), crucial for the proper assembly of the 
effector transcription complex of Notch/RBPjk/MAML1 (Kurooka, 1998); in fact, the 
ANK domain, together with the RAM domain, interacts with the transcriptional 
complex CSL and mediates the signaling transduction; 
• two nuclear localizing sequences (NLS), upstream and downstream of the ANK 
domain, necessary to target the intracellular domain to the nucleus where the TAD 
domain activates downstream events. 
• a OPA region which is rich in glutamine region, has been shown to be a transcription 
activation domain (TAD), important for the transcriptional activation (Notch 3 and 4 
lack of TAD domain) (Kurooka, 1998); 
• a series of conserved proline/glutamic acid/serine/threonine-rich motifs (PEST domain) 
on the very C-terminus, involved in Notch protein degradation by proteolysis (whose 
mutation leads to increased receptor stability , a condition that closely correlates with 
cancer). 
 
Figure 1.1.1. Architecture of Notch1 receptor. In the EGF repeat region the Ca2+ binding EGF 
domain is green and non-Ca2+ binding EGF domain is blue. 
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1.2 NOTCH LIGANDS 
Notch ligands are type I transmembrane proteins (fig. 1.2.1). The largest class is 
characterized by three structural motifs: 
• a N-terminal Delta/Serrate/LAG-2 (DSL) motif; 
• tandem EGF repeats called Delta and OSM-11-like proteins (DOS); 
• EGF-like repeats, some calcium biding and some not. 
Both DOS and EGF-like domains play a role in receptor binding. The ligands can be 
divided based on the presence or absence of a cysteine-rich domain in Jagged/Serrate or 
Delta-like, respectively. Mammals display five canonical Notch ligands, JAGGED1-2 and 
DELTA-like-1,-3,-4 (DLL-1, DLL-3, DLL-4). All of them belong to the DLS/DOS/EGF 
ligand, except for DLL-3 and DLL-4, that lack of the DOS domain. (Cordle, 2008). 
Moreover, recent study by D’Souza and colleagues has reported additional noncanonical 
ligands for Notch receptors, lacking DSL and DOS domains (F3/Contactin1, NB-
3/Contactin6, DNER, MAGP1, and MAGP2). The physiological functions for these 
proteins in the Notch pathway remain to be explored (D’Souza, 2008). 
 
 
Figure 1.2.1. Architecture of Jagged1. Human Jagged-1 is represented in the figure. Similar to the 
Notch receptor, much of the extracellular region comprises EGF repeats 
 
1.3 NOTCH MATURATION, ACTIVATION AND SIGNAL TRANSDUCTION  
 
Notch receptor maturation/activation is an irreversible process as it involves proteolysis-
mediated maturation and release of the Notch intracellular domain, translocation to the 
nucleus, and association with a DNA-bound protein (fig 1.3.1 and 1.3.2). 
 
1.3.1 Notch maturation 
Notch proteins are initially synthesized in the endoplasmic reticulum as 300-350 kDa full-
length unprocessed precursors (pre-Notch), a single polypeptide which undergo proteolytic 
cleavage in the trans-Golgi network before reaching the cell surface. During its 
translocation, post-translational modifications occur: a fucose is attached by the O-fucosil-
transferase POFUT1, in an O-linkage manner, to a Ser or Thr residue that occurs right 
before the third cysteine of the EGF12 region. O-linked fucose (O-fucose) can be further 
elongated by the action of another glycosyltransferase, Fringe (Manic Fringe in mammals), 
which attaches N-acetylglucosamine (GlcNAc) in a β1,3 linkage to EGF-O-fucose 
(Okajima, 2003). 
Notch glycosilations are necessary to transport the pre-Notch protein from the endoplasmic 
reticulum to the Golgi apparatus where the first cleavage is mediated by a furin-like 
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convertase and occurs within HD domain at a site referred to as the S1 cleavage site (at 70 
amino acids from the transmembrane domain), converting the pre-Notch polypeptide into 
the heterodimer NECD/NTMIC (Notch-extracellular domain/Notch transmembrane and 
intracellular domain) (Blaumueller, 1997; Logeat, 1998). The two subunits resulting from 
this process are brought to the plasma membrane as one heterodimer, held together by non-
covalent calcium-dependent interactions. 
 
Post-translational modifications of Notch can modulate Notch ligand interactions since 
Fringe enzyme is expressed only in a subset of cells and this seems to influence the Notch 
activation. In cells expressing Fringe, Notch ligands show distinct preferences: Delta-like 
prefers Fringe-modified Notch, whereas Serrate-like would much rather bind unmodified 
Notch. These preferences are the basis for Notch hyperactivation at boundaries between 
Fringe expressing and -nonexpressing territories, but the relative importance of each site 
glycosylated and the molecular basis for this regulation is unknown (Okajima, 2003). 
 
1.3.2 Notch activation 
The Notch signaling is a cell-to-cell communication pathway that is activated when Notch 
ligand on the sending cell bind to Notch receptor on the receiving cell (Schroeter 1998). 
The binding of ligand on Notch receptor triggers conformational modifications in the Notch 
protein which cause a sequence of proteolytic cleavages terminating in Notch trans-
activation (Brown, 2000; Mumm, 2000). 
This process is characterize by two steps: 
• Following ligand binding, Notch signaling is initiated when endocytosis of the ligand–
NECD complex induces unfolding of the juxtamembrane negative control region 
(NRR). In particular, the DSL ligand epsin-mediated endocytosis is triggered by 
monoubiquitination of the intracellular domain  mediated by the E3 ubiquitin ligases 
Neuralized (which preferentially recognizes Delta ligands) and Mindbomb (which 
recognizes Serrate/Jagged). The resulting conformational change in NRR exposes site 2 
(S2) in Notch for the first activating cleavage allowing access by ADAM/TACE (A 
disintegrin and metalloprotease/tumor-necrosis-factor α converting enzyme) 
metalloprotease. The S2 cleavage occurs within the extracellular domain, approximately 
12 amino acids before the transmembrane domain at a site referred to as the S2 cleavage 
site (Brou, 2000; Mumm, 2000). This is a key regulatory step in Notch activation, but 
some ambiguity still exists regarding the enzymes that mediate the cleavage: while 
ADAM17/TACE seems to be the main metalloprotease able to cleave Notch receptors 
in vitro (Brou, 2000), animal models point to ADAM10/Kuzbanian metalloprotease for 
this essential function in vivo (van Tetering, 2009, Lieber, 2002). ADAM proteases 
leaves a short-lived fragment anchored to the plasma membrane, called NEXT (Notch 
extracellular truncation). 
• NEXT becomes the substrate for the last cleavage: Notch intracellular fragment is 
recognized by the inactive aminopeptidase domain of Nicastrin (NCT), which transfers 
NEXT to the active site of γ-secretase which operate the cleavage within the 
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transmembrane domain, in particular between  site S3 (near the inner plasma 
membrane) and site S4 (near the middle of the transmembrane domain. The γ-secretase 
is an aspartyl-protease presenilin(s) complex comprising of four core proteins 
(presenilin 1 or 2, anterior pharynx defective 1 (APH1), nicastrin, and presenilin 
enhancer 2 (PEN2) (De Strooper, 1999; Francis, 2002). γ-secretase cleavage can occur 
at the cell surface or in endosomal compartments, perhaps following 
monoubiquitination. The apical polarity protein Crumbs appears to play a role in 
restricting γ-secretase activity thereby limiting the extent of Notch activation (Kopan, 
2009). 
The γ-secretase-mediate processing, releases the Nβ peptide (which can escape the lipid 
bilayer and is degraded) and various forms of NICD: only those that have valine residue 
at the amino terminus (V1744), escape the N-end-rule degradation pathway (Tagami,  
2008) and are stable enough to translocate into the nucleus, where it interacts with the 
DNA-binding protein complex CSL [CBF-1 (Cp-binding factor 1)/ RBP-Jk 
(recombination signal sequence-binding protein Jk)] to impact transcription. 
 
1.3.3 Notch signal transduction 
Into the nucleus, in absence of activation by Notch, it has been demonstrated that CSL acts 
as a transcriptional repressor due to its ability to bind several transcriptional co-repressor 
complexes including SMRT (silencing mediator of retinoic acid and thyroid hormone 
receptor), histone deacetylase 1 (HDAC1), HDAC2, SHARP (SMRT/HDAC1-associated 
repressor protein), CIR1 (CBF1-interacting co-repressor) and SKIP (ski-related protein) 
(Mumm, 2000). These proteins facilitate nuclear localization of CSL and repress 
transcription from target genes (Zhou, 2001). 
When ICN translocate into the nucleus, RAM region of NICD binds CBF-1 displacing  co-
repressor complexes; CSL is converted in a transcriptional activator by SKIP, and finally, 
the ANK region of NICD (still associates to CSL), recruits the transcriptional co-activator 
Mastermind-like1 (MAML1) (Wu, 2004) and several different transcriptional co-activators 
including histone acetyltransferase p300, PCAF and GCN5 (Osborne, 2007); this new 
assembly transcription complex binds the promoters of target genes harboring CBF-1-
binding sites, providing an additional stimulus for transcription of Notch downstream target 
genes (Artavanis-Tsakonas, 1999).  
Thus, every cleaved Notch molecule generates one signaling unit, and tuning the 
effectiveness of receptor– ligand interaction directly determines the amount of NICD in the 
nucleus. 
The rapidly changing levels of pathway activity require that the nuclear effectors do not 
have a long half-life; in fact the assembly of the co-activator complex not only promotes 
transcription, but also results in turnover of Notch: NICD is phosphorylated on its PEST 
domain by the CDK8 kinase and targeted for proteasomal degradation by the E3 ubiquitin 
ligase Fbw7Sel10 (Fryer C.J.,2004). NICD degradation resets the cell and prepares it for 
the next round of Notch signaling. 
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Figure 1.3.1. Schematic representation of the proteolytic cascade upstream Notch activation. 
 
 
 
HD 
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Figure 1.3.2. Notch canonical pathway. After translation, Notch receptor pre-protein is glycosylated 
by Ofut, essential enzyme for the production of a  functional receptor. PC5/furin protease produces 
the mature receptor cleaving Notch at site 1 (S1). Then, Notch reaches  the cell surface as a 
heterodimer, held together by noncovalent interactions. The glycosyltransferase Fringe extends the O-
fucose, thereby altering the ability of specific ligands to activate Notch. The Notch receptor is 
activated by a ligand presented by a neighboring cell. Endocytosis and membrane trafficking regulate 
ligand and receptor availability at the cell surface. Ligand endocytosis promotes a conformational 
change in the Notch receptor. Such conformational change exposes site 2 (S2) in Notch for cleavage 
by ADAM metalloproteases. S2 cleavage generates the NEXT fragment (membrane-anchored Notch 
extracellular truncation), a substrate for the γ-secretase complex. γ-secretase cleaves NEXT 
progressively from site 3 (S3) to site 4 (S4) releasing the Notch intracellular domain (NICD) and Nβ 
peptide. γ-Secretase cleavage can occur at the cell surface or in endosomal compartments, but 
cleavage at the membrane favors the production of a more stable form of NICD. NICD then enters the 
nucleus where it associates with the CSL (CBF1/RBPjκ/Su(H)/Lag-1) complex. In the absence of 
NICD, CSL associates with corepressor (Co-R) proteins and histone deacetylases (HDACs). NICD 
binding facilitates displacement of transcriptional repressors. Then, Mastermind (MAM) coactivator 
recognizes the NICD/CSL interface, and this triprotein  complex recruits additional coactivators (Co-
A) to activate transcription. 
 
In addition to trans-activating Notch–ligand complexes, the receptor can also form cis-
inhibitory complexes when binding occurs between Notch and ligand expressed on the 
same cell surface. Cis-inhibition serves to limit the zone of Notch activity and thus 
determine whether a cell will signal (the ligand is more abundant than Notch) or 
receive (Notch is more abundant than the ligand) (Sprinzak, 2010). Alternatively, in 
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some cases ligand and receptors can be segregated into different subdomains to allow 
simultaneous transmission and reception of signals (Luty, 2007) (fig.1.3.3). 
Some recent reports show that ligands also undergo proteolysis (LaVoie 2003) and release 
ligand intracellular domain (LICD) which antagonizes Notch signalling by mechanisms as 
yet unclear. 
 
 
Figure 1.3.3. Trans- and Cis-activation of Notch. In trans-activation, a ligand from the 
neighbouring cell binds to the receptor leading to Notch activation. Receptor and ligand present on 
the same cell surface can also bind to each other leading to cis-inhibition. 
 
 
The Notch signaling is the result of a fine-tuned balance; both Notch and Notch ligands are 
in a dynamic equilibrium between a PM pool and an intracellular vesicle pool, with a 
transition to internalized pool upon interaction of adjacent cells. 
Endocytosis of the Notch receptor is tightly controlled in time and space: Numb, a 
conserved membrane-associated protein is a a well characterized Notch inhibitor that acts 
upstream of the γ-secretase cleavage, in cooperation with the AP2 component α-adaptin (a 
protein that that links cargoes to clathrin coats of transport vesicles) and NAK (Numb 
associated kinase); Numb is asymmetrically segregated into one of two daughter cells in 
several lineages, thus, when Numb interacts with the ear domain of α -adaptin and with 
Notch, in can directly recruit Notch into endocytic vesicles and block Notch signaling in 
daughters of a asymmetric dividing cells. Furthermore, mammalian Numb promotes Notch 
ubiquitylation. 
Several E3 ubiquitin ligases, e.g. Deltex, Nedd4, Sel-10, API/Itch and Su(dx),can control 
Notch receptor trafficking either towards lysosomal degradation or recycling,: modifying 
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Notch they target it for degradation influencing its endosomal and multivesicular-body-
sorting pathway (Bray, 2006; Kopan, 2009). 
ESCRT (Endosomal sorting complex required for transport) complex and LGD (Lethal 
Giant Discs) have a rule in the accumulation of Notch in a late endosomal vesicle, to 
maintain Notch in the OFF state. 
Also ubiquitinylated ligands following endocytosis are proposed to be targeted to 
endosomes in order to become active and then recycled to the plasma membrane rather than 
being degraded.  
Ligands are ubiquitinated by the E3 ubiquitin ligases, Neur and Mib, triggering ligand 
endocytosis, trough the ubiquitin-binding protein Epsin  and the J-domain-containing 
protein Auxilin (which can disassemble clathrin coats). In this Epsin-mediated processing, 
an undefined modification produces an active ligand that recycles to the cell surface in a 
Rab11-dependent manner. 
Probably, ubiquitylation permits trafficking into an endocytic compartment, which enables 
ligand modification and activation or results in re-insertion of the ligand into specific 
membrane domains: the localization of ligands within the cell is important for effective 
signalling and might be influenced in this way (Bray, 2006; Kopan, 2009). 
 
1.4 NOTCH TARGET GENES 
Although signals mediated through Notch receptors have diverse outcomes, only a fairly 
limited set of Notch target genes have been identified in various cellular and developmental 
contexts. 
The most exstensively studied and best understood targets are Hairy and Enancer of Spleet 
in Drosofila and the related genes Hes and Hey in mammals. In mammals genome seven 
Hes (Hes 1-7) and three Hey (Hey 1, 2, L) genes have been identified. However, only Hes 
1, 5, 7, as well as all Hey genes are induced by Notch activation. HES and HEY are helix-
loop-helix transcription factors that function as a transcriptional repressors and play an 
important role in development.  
CD25 (IL2-R and preTa, pre-T-cell receptor alphachain) and the transcription factor 
GATA3 are direct Notch target genes activated in T-cell development. Two other Notch 
target genes NRARP and Deltex1 are shown to be negative regulators of Notch signaling 
itself. Further Notch targets are Myc, CyclinD1, p21/Waf1, Bcl2, E2A, HoxA-5 -9 -10, 
NFκB2, Ifi-202, Ifi-204, Ifi-D3, and ADAM19. Notch1 and Notch3 have been reported as 
Notch itself target genes (Borggrefe, 2009). 
Interestingly, bearded family members, which negatively regulate Neuralized activity and 
thus, reduce the efficiency of Notch activation by Delta, are themselves Notch target genes 
(Lai, 2000) thereby forming a negative feedback loop. 
 
1.5 NON-CANONICAL NOTCH PATHWAYS 
Non-canonical Notch signaling is well documented (Talora, 2008; Sanalkumar,  2010), but 
less characterized than the canonical pathway. There are probably three types of non-
canonical Notch signalling:  
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Type I involves Notch ligation and translocation of activation signals independent of CBF1 
(NICD-dependent / CBF1-independent); 
Type II involves Notch activity in a S3 cleavage-independent manner (NICD- and CBF1-
independent);  
Type III involves CBF1-dependent gene activation without receptor cleavage and NICD 
release (Sanalkumar,  2010). 
Several signalling pathways are involved, including Hedgehog, Jak/STAT, RTK, TGF, 
Wnt, PI3/Akt, mTor/Akt, JNK, MEK/ERK, and NFκB (Talora, 2008; Sanalkumar,  2010). 
Non-canonical Notch signalling seems important for maintenance of lineage-restricted 
hematopoietic progenitors, and several of the mediators involved in this signaling are in 
addition important in leukemogenesis as well as regulation of cellular immune responses. 
The non-canonical pathway thus represents a point of crosstalk between other intracellular 
signaling pathways. 
Interactions between Notch and the Wnt pathway have been best characterized, but other 
interactions with various pathways have also been described. 
• Notch/Wnt/ β-catenin signaling:  Wnt signalling is mediated through the downstream 
β-catenin. The Wnt and Notch pathways seem to act in synergy for example to maintain 
the stem cell pool. The crosstalk between these two pathways seems to occur both at 
transcriptional  level and at protein interaction level. Members of the Wnt pathway 
regulate the expression of established Notch target genes since the inhibition of Wnt 
signalling affects the expression of both Wnt and Notch target genes as well as the 
expression of Notch1. Another example of crosstalk between these two pathways in the 
stem cell niche is the induced expression of Notch ligands by activated β-catenin in 
stromal cells which thereby induce-Notch-mediated intracellular signalling in adjacent 
cells. Also Notch is able to interact directly and inactivate the β-catenin complex, but 
this signaling is in equilibrium with the Notch inhibition Wnt-mediated (Blank, 2008; 
Staal, 2010; Trowbridge, 2006; Reya, 2003; Yamane, 2001; Hayward, 2005) (fig.  
1.5.1). 
• Notch/mTor/AKT signaling: Akt is a key downstream target in the antiapoptotic 
pathway activated by Notch. Nuclear functions of ICN is shown to be not essential for 
this pathway which is independent by the transcription factor, CBF1. NIC activity is 
initiated by a membrane-anchored form of ICN that converges on the kinase 
mammalian target of rapamycin (mTOR) and the substrate-defining protein rapamycin 
independent companion of mTOR (Rictor), triggering the activation of the kinase 
Akt/PKB and consequently cell survival (Perumalsamy, 2009) (fig. 1.5.2). 
• Notch/NF-κB signaling: several reports have proposed direct interactions of Notch1-IC 
with NF-κB subunits (Wang, 2001; Espinosa, 2003; Oakley, 2003) and very recent 
work has demonstrated that ICN interacts with NF-κB and competes with the IkBα 
protein, enhancing the retention of Nfkb1 and Rel in the nucleus (Shin, 2006). Notch1 
also regulates the NF-κB pathway by inducing the expression of Relb and Nfkb2 and by 
a direct  interaction of Notch1 with the IKK complex which stimulates the activity of 
IKK (Vilimas, 2007). In addition, activation of NF-kB may also be mediated by 
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Notch3: Notch3 seems to be a direct transcriptional target of Notch1 (Palomero, 2006; 
Vilimas, 2007) and recent work shows that Notch3 can activate the NF-κB pathway by 
phosphorylating IKKα homodimers, which in turn activate the noncanonical p52-Relb 
NF-κB pathway (Vacca, 2006). Thus, in principle, Notch-1 could activate the NF-κB 
canonical signaling by activating the IKKα/β/γ signalosome and facilitating the nuclear 
retention of NF-κB heterodimers, and the noncanonical pathway by inducing the 
expression of Relb and Nfkb2 and activating IKKα homodimers via Notch-3. 
 
 
Figure 1.5.1. Modulation of Wnt signalling by Notch in Drosophila (Hayward 2005). In the steady 
state, β-catenin exists in a number of molecularly distinct pools which appear to be in equilibrium. β-
catenin associates readily with Cadherin and participated in the dynamics of adherens junctions. On 
the other hand, β-catenin association with a complex (comprising of Axin, APC, GSK3ß and CSK1α), 
leads to its phosphorylation on the N terminus by GSK3ß and the delivery of the β-catenin 
phosphorylated form to the proteasome where it is degraded. Axin acts as a scaffold for GSK3ß 
mediated phosphorylation and also can prevent the formation of β-catenin/ TCF active complex in a 
GSK3ß independent manner. It was shown that Notch modulates the activity and amounts of β-
catenin either by direct contact or by targeting the activity of Axin. Wnt signaling through a 
Frizzled/Arrow (FZD) heterodimer activates Dishevelled (DSH) which inhibits the inactivating 
complex, destroying Axin and inhibiting the N terminal phosphorylation of β-catenin. Wnt has been 
shown to bind to the extracellular domain of Notch  and Dishevelled to the intracellular domain and 
this binding is likely to be responsible for down regulating the modulatory activity of Notch. The net 
effect of the inactivation of Notch and the Axin based complex results in an efficient accumulation of 
Armadillo in the nucleus and its interaction with TCF. 
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Figure 1.5.2. Interaction of NICD with components of other signaling pathways to activate Notch 
targets or tissue-specific factors 
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2. THE ROLE OF NOTCH IN PHYSIOLOGICAL AND 
PATHOLOGICAL SYSTEMS 
 
2.1 NOTCH IN PHYSIOLOGICAL PROCESSES 
The Notch pathway is involved during diverse developmental and physiological processes, 
in which its signaling occurs between adjacent cells to direct them to adopt different cell 
fates. These cell-fate decisions can be categorized, based on cellular outcome, into three 
distinct models (fig.2.1.1): 
• Lateral inhibition in which Notch signaling amplifies small or weak differences within 
roughly equivalent populations of cells. In this system, a population of equivalent cell 
share developmental potential but only some achieve a specific fate. Cells that adopt 
that fate, activate Notch in neighbor cells in order to prevent them from acquiring the 
same fate. This process is involved in morphogenesis (e.g. tooth, lung, hair), in 
boundary formation (e.g. wing, somtes, limb), in cell specification (e.g. CNS, pancreas) 
and apoptosis (e.g. neural crest cells). It is not clear how a difference arises in the first 
cell. 
• Lineage decision, in which Notch signalling between two daughter cells is dependent 
on asymmetrical inheritance of Notch or its regulators (for example, Numb); this step  is 
sequential to cell fate assignation. 
• Inductive signal (boundaries signal) where Notch induces rather then selects new cell 
fate: Notch signalling occurs between two populations of cells and can establish an 
organizer and/or segregate the two groups (Haines, 2003). 
 
Figure 2.1.1. The Notch signalling pathway is used for a wide range of cell-fate decisions, but most 
instances fall into one of a few distinct modes, such as lateral inhibition, decisions on cell-lineage or 
inductive signalling. a | Lateral inhibition: a pair or a group of equivalent precursor cells (light 
purple) signal through the Notch pathway to inhibit each other's ability to adopt a distinct fate. In a 
sequential process (shown by the arrows), which is amplified by feedback loops, one cell in each 
group (dark purple) 'wins' by lacking Notch activation. Notch activation in the other cells results in 
an alternative cell fate (yellow). b | Asymmetric cell divisions: at each cell division, Notch is activated 
in one daughter cell (solid lines) but not in the other cell (dashed lines), which results in the adoption 
of distinct cell fates (indicated by different colours). c | Inductive signalling: one group of cells 
(yellow) signals (orange arrows) to a distinct neighbouring group of cells (green) to induce a new 
cell fate along the interface between them (red). 
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Notch receptors and ligands are widely expressed during organogenesis in mammalian 
embryos, and studies of spontaneous or induced mutants demonstrate that Notch signaling 
regulates cell lineage decisions in tissues derived from all three primary germ layers: 
endoderm (e.g. pancreas), mesoderm (skeleton,mammary gland, vasculature, and 
hematopoietic cells), and ectoderm (neuronal lineages). Some developing tissues express 
several different receptors and ligands, whereas others express a single receptor–ligand 
pair. Although some Notch receptors appear to have genetically redundant functions in 
some developmental contexts (e.g. N1 and N4 in vasculogenesis) (Krebs, 2000), others 
have unique and essential functions as revealed by the severe disruption of embryogenesis 
that results from loss-of-function mutations. 
In the following paragraph are reported the main physiological processes in which Notch is 
involved: 
Notch signaling in embryogenesis 
The Notch signaling pathway plays an important role in cell fate determination during 
embryonic development. Notch signaling is required in the regulation of embryo polarity 
and  during left-right asymmetry determination in vertebrates. 
Notch signaling is central to somitogenesis and in the maintenance of somite borders. 
Recent studies hypothesized that the primary function of Notch signaling does not act on an 
individual cell, but coordinates cell clocks and keep them synchronized (Austin, 1987; 
Levin, 2005; Conlon, 1995). 
Notch signaling in central nervous system development and function 
The Notch signaling pathway was mainly found to be critical for neural progenitor cell 
(NPC) maintenance and self-renewal as well as cell fate specification. In recent years, other 
functions of the Notch pathway have also been found, including glial cell specification, 
neurites development as well as learning and memory. 
In gliogenesis, Notch appears to have an instructive role which can directly promote the 
differentiation of many glial cell subtypes For example, activation of Notch signaling in the 
retina favors the generation of Muller glia cells at the expense of neurons, whereas reduced 
Notch signaling induces production of ganglion cells, causing a reduction in the number of 
Muller glia. 
In addition to developmental functions, Notch proteins and ligands are expressed in cells of 
the adult nervous system, suggesting a role in CNS plasticity throughout life. Adult mice 
heterozygous for mutations in either Notch1 or Cbf1 have deficits in spatial learning and 
memory  (Furukawa, 2000; Scheer, 2001; Redmond, 2000; Costa, 2003; Bolo´s,  2007). 
Notch signaling in cardiovascular development 
The Notch signaling pathway is a critical component of cardiovascular formation and 
morphogenesis in both development and disease. It is required for the selection of 
endothelial tip and stalk cells during sprouting angiogenesis.  
Notch signal pathway plays a crucial role in at least three cardiac development processes: 
Atrioventricular canal development (in the boundary formation between the AV canal and 
the chamber myocardium), myocardial development as well as cardiac outflow tract (OFT) 
development.  Notch may regulate this process by activating matrix metalloproteinase2 
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(MMP2) expression, or by inhibiting vascular endothelial (VE)-cadherin expression in the 
AV canal endocardium while suppressing the VEGF pathway via VEGFR2.  
The downstream effector of Notch signaling, HEY2, was also demonstrated to be important 
in regulating ventricular development by its expression in the interventricular septum and 
the endocardial cells of the cardiac cushions (Kume, 2012; Niessen, 2008; Kokubo, 2007; 
Timmerman, 2004; Nemir, 2006) 
Notch signaling in angiogenesis 
Endothelial cells use the Notch signaling pathway to coordinate cellular behaviors during 
the blood vessel sprouting that occurs in angiogenesis.  
Activation of Notch takes place primarily in “connector” cells and cells that line patent 
stable blood vessels through direct interaction with the Notch ligand, Delta-like ligand 4 
(Dll4), which is expressed in the endothelial tip cells. VEGF signaling, which is an 
important factor for migration and proliferation of endothelial cells, can be downregulated 
in cells with activated Notch signaling by lowering the levels of VEGF receptor transcript.  
Notch signaling may be used to control the sprouting pattern of blood vessels during 
angiogenesis. When cells within a patent vessel are exposed to VEGF signaling, only a 
restricted number of them initiate the angiogenic process. VEGF is able to induce Dll4 
expression. In turn, Dll4 expressing cells down-regulate VEGF receptors in neighboring 
cells through activation of Notch, thereby preventing their migration into the developing 
sprout. Similarly, during the sprouting process itself, the migratory behavior of connector 
cells must be limited to retain a patent connection to the original blood vessel (Hellstrom, 
2007; Lobov, 2007; Siekmann, 2007). 
Notch signaling in pancreatic development 
The formation of the pancreas from endoderm begins in early development. The expression 
of elements of the Notch signaling pathway have been found in the developing pancreas, 
suggesting Notch signaling is important in pancreatic development. Evidence suggests 
Notch signaling regulates the progressive recruitment of endocrine cell types from a 
common precursor, acting through two possible mechanisms. One is the “lateral 
inhibition,” which could explain the dispersed distribution off endocrine cells within 
pancreatic epithelium. A second mechanism is “suppressive maintenance,” which explains 
the role of Notch signaling in pancreas differentiation (Apelqvist, 1999;  Lammert, 2000; 
Jensen, 2000)  
Notch signaling and intestinal development 
The role of Notch signaling in the regulation of gut development has been indicated in 
several reports. Transcriptional analysis and gain of function experiments revealed that 
Notch signaling targets Hes1 in the intestine and regulates a binary cell fate decision 
between adsorptive and secretory cell fates (Crosnier, 2005)  
Notch signaling and bone development 
Early in vitro studies have found the Notch signaling pathway functions as down-regulator 
in osteoclastogenesis and osteoblastogenesis (Yamada, 2003). Notch1 is expressed in the 
mesenchymal condensation area and subsequently in the hypertrophic chondrocytes during 
chondrogenesis. Overexpression of Notch signaling inhibits bone morphogenetic protein2-
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induced osteoblast differentiation. Overall, Notch signaling has a major role in the 
commitment of mesenchymal cells to the osteoblastic lineage and provides a possible 
therapeutic approach to bone regeneration (Watanabe, 2003; Nobta, 2005).  
Notch signaling in hematopoiesis and lymphocyte development 
Notch receptors and ligands are widely expressed in hematopoeitic tissues and organs, and 
many studies have shown that Notch signaling plays important roles at several stages of 
hematopoiesis (fig. 2.1.2) (Pear, 2003; Radtke, 2002; Ohishi, 2003). For example, enforced 
activation of N1 signaling in hematopoietic stem cells (HSC) can promote their ability to 
self-renew and suppress their differentiation into myeloid, erythroid, or lymphoid lineages 
(Karanu, 2000; Varnum-Finney, 2000; Carlesso, 1999; Varnum-Finney, 2003; Stier, 2002). 
Interestingly, studies of N1-deficient murine embryos have shown that N1 is required for 
the generation of HSC from hemogenic endothelial cells during the initial stages of 
definitive hematopoiesis in the embryonic para-aortic splanchnopleura (Kumano, 2003). 
Notch signaling influences cell-fate decisions at a number of stages of lymphocyte 
development (Allman, 2002). Although T lymphocytes develop in the thymus and B cells 
develop in the bone marrow, both lineages are thought to arise from a common lymphoid 
progenitor (LP) generated in the bone marrow (Kondo, 2001). Conditional ablation of N1 
from HSC/LP profoundly blocks T-cell development at the earliest stages, whereas 
constitutively active N1 (ICN) prevents LP from generating B lymphocytes. 
T-cell lineage commitment is mediated by Notch1/CSL-dependent signaling in a non-
redundant manner (Radtke, 2004) since no T cell phenotype is observed after inducible 
inactivation of Notch-2 -3 -4 in the hematopoietic system (Saito, 2003; Krebs, 2003; Krebs, 
2000). 
Interestingly, an important function of N1 in this cell-fate choice is to ensure that T and B 
cells develop in different tissues (in thymus and bone marrow respectively), since it was 
shown that LP expressing ICN1 ectopically generate T-lineage cells in the bone marrow 
(Pui, 1999), whereas N1-deficient LP ectopically produce B-cells in the thymus (Wilson, 
2001). Thus, N1 activation must be appropriately regulated to ensure that LP generate B 
cells in the bone marrow and T cells in the thymus, but how this is achieved is not yet clear. 
Notch modulators such as Deltex, Numb and Lunatic Fringe may be involved, because they 
can redirect LP to adopt a B-cell fate in the thymus (Izon, 2002; Koch, 2001). 
B cells are able to develop in the BM compartment despite the fact that Notch receptors and 
ligands are expressed on BM progenitors and stromal cells, because Pax5 (the B lineage 
commitment factor) represses Notch1 expression at the transcriptional level in B-cell 
progenitors, providing a possible mechanism to ensure B-cell development in the BM 
(Souabni, 2002). 
N1 also regulates later stages of T-cell development in the thymus (Guidos, 2002), whereas 
N2 regulates B-cell maturation in the spleen (Saito, 2003). 
In T-cell development, the most immature thymocytes are CD4 and CD8 double negative 
(DN), and those precursors that have in-frame rearrangements of the T-cell receptor (TCR)-
β locus, receive pre-TCR signals that drive them to proliferate extensively and mature into 
the CD4/CD8 double positive (DP) intermediate stage. Most DP thymocytes die, but those 
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that express an αβ-TCR complex with appropriate ligand specificity are positively selected 
to mature into CD4+ or CD8+ T cells. It is unclear whether Notch signaling influences γδ -T 
cell development. N1 activation crucially regulates either the expression or function of the 
pre-TCR (Wolfer, 2002), and culture of pre-TCR-expressing thymocytes with Dll-1-
expressing cells induces their proliferation and maturation in vitro (Huang ,2003). 
Although N1 is not essential for CD4 or CD8 T-cell development (Wolfer, 2001), but a 
number of studies have supported a role for N1 in CD4-/CD8-lineage commitment and the 
maturation/survival of CD4 and CD8 cells (Robey, 1996; Deftos, 2000; Fowlkes, 2002). 
Most Notch ligands are expressed in the thymus, but which ones are essential for T-cell 
commitment and maturation are not yet clear. 
The final intrathymic cell fate decision is made by αβ-T-cells as CD4+ CD8+ (DP) 
thymocytes migrate to the periphery where they must choose to adopt either a CD4+ T 
helper- or a CD8+ cytotoxic-T-cell fate (Deftos, 2000; Robey, 1996; Izon, 2001; Deftos, 
1998; Fowlkes, 2002). 
Notch1 seems to directly regulate expression of eomesodermin which is a transcriptional 
regulator in CD8+ cytotoxic T cells (Cho, 2009); in T-h1 cell fate, DLL ligands (DLL1 
and/or DLL4) seem to promote Th1 and inhibit Th2 differentiation (Radtke, 2010), while in 
T-h2 seems to be involved trough the Th2-specific transcription factor Gata3 which is a 
Notch target gene (Jurynczyk, 2008). But the additional molecular events in this 
differentiations have not been characterized  
In B-cell development, expression levels of Notch2 increase with B-cell maturation and are 
highest in splenic B-cells suggesting a role for Notch signalling in peripheral B-cell 
development and/or function, the Notch2 gene induces maturation of a particular splenic B-
cell subset located on the margin of the B cell follicle at the blood–lymphoid interface, 
known as marginal zone B (MZB) cells (Saito, 2003).  MZB cells respond to blood-borne 
viral and bacterial agents. Their rapid activation and differentiation into antibody-secreting 
plasma cells helps to bridge the gap between innate and adaptive immunity, the latter of 
which is mainly effected by follicular B-cells (FoB) (Lopes-Carvalho, 2004; Pillai, 2005). 
In FoB cells, Notch pathway is not active because of the presence of MINT factor: MINT is 
a negative modulator of Notch signalling and promotes FoB cells development by 
interacting with RBP-J, thereby inhibiting Notch–RBP-J-binding. MINT is more 
abundantly expressed in FoB cells compared to MZB cells, in fact MINT-deficient mice 
show an increase in MZB cell numbers with a concomitant reduction of FoB cells. These 
reciprocal phenotypes have led to the suggestion that Notch signalling influences the 
commitment of a bi-potential splenic B cell progenitor that has to choose between the MZB 
and FoB cell lineages. 
Identical MZB cell phenotypes have been observed in conditional gene-targeted mice for 
Notch2 and CSL indicating that Delta1-mediated Notch2/CSL signalling specifies MZB 
cell lineage commitment in a non-redundant fashion in vivo. Dendritic cells (DCs) were 
suggested to mediate Notch2 signaling on B cell progenitors based on the fact that DCs 
expressing Delta1 are found in close proximity to MZB cells at the margins of B cell 
follicles (Kuroda, 2003)  
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Figure 2.1.2. Notch signaling in lymphopoiesis. (Radtke, 2004) Bone marrow (BM) HSCs are 
maintained through selfrenewal in stem cell niches in close contact with stromal and/or other 
hematopoietic cells. Jagged1 (J1)–Notch1 (N1) interactions may influence the process of self-
renewal. After commitment to the lymphoid lineage, early lymphocyte precursors (ELP) continue 
differentiation into either B or T cells. In the bone marrow, Notch (N) signalling must be ‘off’ to allow 
pro-B cells to progress through pre-B I and pre-B II stages to immature B cells (Imm B). After 
migration to the periphery, interaction of Delta1 (D1) with Notch2 (N2):CSL induces transitional B 
cells (Trans B) to become MZB cells. In contrast, Mint induces transitional B cells to become FoB 
cells. In the thymus, the early thymus precursor (ETP) requires a Notch1 (N1):CSL signal to develop 
into pro-T cells; otherwise, B lineage development occurs by default. This signal is mediated through 
Delta1. Pro-T cells then require Notch1 signals to efficiently develop into pre-T cells of the αβlineage 
and to undergo successful pre-TCR mediated signaling. It is unclear whether Notch signaling 
influences γδT cell development. Double-positive (DP) thymocytes mature into conventional CD4 or 
CD8 T cells and then migrate to the periphery, where CD4 T cells undergo further differentiation into 
TH1 or TH2 cells. This latter lineage split may be influenced by D1:Notch3 (N3) signaling. CD8 T 
cells undergo further differentiation into cytotoxic-T cell. Regulatory CD25+ CD4 T cells 
(CD25+TR) develop in the thymus from DP T cells, possibly through N3 signaling.  
 
 
2.2 NOTCH AND CANCER 
Given the range of processes that require normal Notch signaling, it is not surprising to find 
that a number of human diseases and cancer are caused by mutation in components of the 
Notch pathway and/or in the deregulation of Notch signaling. Consequences of disruption 
of proper Notch signaling are very diverse (table 2.2).  
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2.2.1 Notch as oncogene 
Notch deregulation is involved both in solid tumors as breast cancer, skin cancer, 
neuroblastomas, prostate cancer and cervical cancer (Allenspach, 2002), and in non-solid 
malignancies, such as leukemia (Weng, 2004) and multiple myeloma (Jundt, 2004). 
From 90’s to nowadays Notch signaling aberrations have been shown to be linked with 
several hematological malignancies such as T-cell acute lymphoblastic leukemia (T-ALL), 
acute myeloid leukemia (AML), lymphoma and MM. The main oncogenic role of Notch 
can be found in T-ALL, an aggressive neoplasm of immature T-cells. In human leukemia, 
Notch 1 activation was initially demonstrated in T-ALL harboring the translocation 
(7;9)(q34;q34.3), a rare chromosomal translocation identified in less than 1% of T-ALL 
cases. As a result of this rearrangement, a truncated Notch-1 gene is juxtaposed next to the 
T-cell receptor β locus, leading to the ligand-independent aberrant expression of a 
constitutively active form of Notch-1 (Koch, 2007).  This translocation is rare in T-ALL 
patients (less than 1%), but approximately 60% of T-ALL cases display activating Notch 
mutations (Weng, 2004). The majority of mutations are located in the HD (between exons  
26 and 27), in the extracellular juxta-membrane (JME) region (exon 28)and PEST (exon 
34) domains. HD mutations are typically single amino acid substitutions and small in-frame 
deletions and insertions that induce ligand-independent activation of Notch, leading to 
constitutive activation of the Notch signaling pathway (Malecki, 2006). PEST mutations 
encodes premature stop codons and lead to generation of truncated forms of Notch lacking 
the PEST domain, resulting in an increased level of active Notch due to its impaired 
proteasomal degradation (Weng, 2004). The HD and PEST domain mutations were found 
in trans in 26% and 12.5%, respectively, and in cis in 17.7% of cases examined. These 
mutant forms of Notch have been demonstrated to increase Notch transcriptional activity in 
vitro. Mutations in the JME region consist of tandem duplications that cause the expansions 
of the extracellular juxtamembrane region, leading to increase distance of the NNR-HD 
complex from the membrane, allowing ligand-independent proteolytic processing of S2 
(Sulis, 2008). Given the causative role of Notch-1 mutations in T-ALL, a large number of 
studies focused on the analysis of Notch mutational status in this malignancy. All the 
reported mutations in T-ALL affected the Notch-1 isoform, while Notch-2,-3 and -4 were 
not found to be altered (Lee, 2007). The main way in which abnormal Notch1 activity 
drives T-ALL is activation of Myc and CyclinD as well as inhibition of p53: all of them 
promote oncogenesis through increased proliferation, survival and genomic instability. 
The role of Notch signaling in AML is less clear than in T-ALL. Activating mutations of 
Notch have been reported but they seems to be a rare event (Palomero, 2006). Chiaramonte 
and colleagues demonstrate that AML primary sample show high levels of Jagged-1 
expression, despite low Notch-1 pathway activation (Chiaramonte, 2005), thus suggesting a 
Notch-independent pathway driven directly by the Jagged-1 ligand (Ascano, 2003). 
Regarding B-cell malignancies, Notch deregulation has been detected in Hodgkin’s 
lymphoma, large B-cell lymphoma, Burkitt’s lymphoma, B-cell chronic lymphocytic 
leukemia, diffuse large B-cell lymphoma, primary effusion lymphomas associated with 
Kaposi’s sarcoma herpes virus infection and in Multiple Myeloma (Mirandola, 2011a). 
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The role of Notch in MM will be discussed in the following chapter. 
 
The second most compelling evidence for a Notch oncogenic function comes from studies 
of breast and cervical cancer as well as melanoma. Molecular analysis reveal that Notch4 
overexpression activates TGF-β and HGF signaling and promotes tumor invasion in the 
majority of breast ductal carcinoma in situ lesions (Meurette, 2009). 
A role for aberrantly active Notch signaling has been proposed in cervical cancer, largely 
due to observation of intensive Notch 1 and 2 protein accumulation as well as consistent 
expression of Jagged1 in which two oncogenic effector mechanisms are triggered by Notch: 
activation of PI3K/AKT pathway and up-regulation of Myc (Maliekal, 2008). 
The Notch signaling is also up-regulated in primary human melanomas: the pro-oncogenic 
role of Notchis linked with activation of WNT signaling and promotion of N-cadherin 
expression (Koch, 2007). 
 
2.2.2 Notch as tumor suppressor 
The most emblematic example of Notch tumor suppressor function comes from studies on 
the skin. Ablation of Notch 1 in murine epidermis leads to epidermal hyperplasia and skin 
carcinoma. The tumor suppressive effect of Notch 1 in the epidermis appears to be 
mediated by induction of p21 (inhibitor of cell cycle) and suppression of Wnt/β-catenin 
signaling which is associated with maintenance of keratinocytes in their stem cell 
compartment thus leading to terminal differentiation by withdrawal of proliferating cell 
from the cell cycle (Nicolas, 2003). 
Zweidler-McKay’s work reported that Notch signaling is a potent inducer of growth arrest 
and apoptosis in a wide range of B-cell malignancies: he tested 13 lines representing 
multiple subclasses of B-cell neoplasias and observed that all the four mammalian Notch 
receptors inhibited growth and induce apoptosis. The effect was observed by both 
expression of constitutively active intracellular Notch, as well as by ligand-induced 
activation of Notch signaling (Zweidler-McKay, 2005). 
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Table 2.2  Involvement of aberrant NOTCH signaling in a wide variety of cancers. NOTCH signaling 
may act as a tumor suppressor or a promoter depending on the cell type and cell context (L.Yin et al, 
2010). 
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3. MULTIPLE MYELOMA 
 
Multiple myeloma is a neoplastic plasma-cell disorder that is characterized by clonal 
proliferation of malignant plasma cells (PCs) in the bone marrow (BM) microenvironment, 
monoclonal protein in the blood or urine and associated organ dysfunction. It belongs to a 
group of related paraproteinaemias, namely diseases that produce an immunoglobulin from 
a single clone that is present at high levels in the serum. They include multiple myeloma 
(MM), monoclonal gammopathy of undetermined significance (MGUS) and 
Waldenstrom’s macroglobulinaemia (WM) (Morgan, 2012).  
MM accounts for 1% of all cancers and about 10% of all hematologic malignancies 
(Rajkumar, 2012). The American Cancer Society estimates that this year 21.700 new cases 
(12.190 in men and 9.510 in women) will be diagnosed in the United States, and that 
10.710 deaths will occur in 2012 as result of MM (ACS, 2012). The median age at 
diagnosis is about 65 years (Kyle, 2004a) and is slightly more common in men than in 
women and is twice as common in African-Americans compared to Caucasians (Landgren, 
2009). 
The presence of somatic hypermutations of the immunoglobulin variable region genes in 
myeloma plasma cells suggests that malignant transformation occurs in a B cell that has 
traversed the germinal centers of lymph nodes. However, the hypoproliferative nature of 
myeloma has led to the hypothesis that the bulk of the tumor arises from a transformed B 
cell with the capacity for both self-renewal and production of terminally differentiated 
progeny (Harousseau, 2004). Almost all patient with MM evolve from the asymptomatic 
premalignant stage of MGUS, which affects at least 3% of adults older than 50 years 
(Weiss, 2009). Moreover, in some cases, MM arises from another asymptomatic but more 
advanced premalignant stage, referred as smoldering multiple myeloma (SMM). The risk to 
progress from SMM to MM was 10% per year in the first 5 years, 3% per year for the next 
5 years and 1% per year for the last 10 years, reaching a cumulative probability of 
progression of 75% at 15 years (Kyle, 2007). 
 
3.1 DIAGNOSIS 
The diagnosis of MM requires at least 10% or more clonal plasma cell on bone marrow 
examination or a biopsy proven plasmacytoma and evidence of end-organ damage 
(hypercalcemia, renal insufficiency, anemia or bone lesions) that is ascribed to the 
underlying plasma cells disorder. When MM is clinically suspected, patients should be 
tested for the presence monoclonal proteins (M proteins) through a series of test, such as 
serum protein electrophoresis (fig. 3.1.1), serum immunofixation and serum-free light chain 
(FLC) assay (Rajkumar, 2012).  
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Figure 3.1.1 a- Serum protein electrophoresis showing a paraprotein (peak in the gamma zone) in a 
patient with multiple myeloma. b- A skull X-ray shows the classic “punched-out” lytic bone lesions. 
 
Three main staging systems have been developed during the years, namely Durie/Salmon 
system (Durie, 1975), the International Staging System (ISS) (Greipp, 2005) and the latest 
Mayo Stratification of Myeloma and Risk-Adapted Therapy (mSMART) guidelines 
(Dispenzieri, 2007). All the three systems classify the patients in three risk categories (table 
3.1), termed as stage I, II and III by Durie/Salmon and ISS classifications, while low, 
intermediate and high risk by mSMART classification. While the previous staging systems 
evaluated mainly blood values such as hemoglobin, M proteins, calcium, albumin, 
creatinine and β2-microglobulin, mSMART guidelines introduced molecular cytogenetic 
markers to assess disease aggressiveness, taking into consideration hyperdiploidy and 
several recurrent chromosomal aberrations. Patients with standard risk have a median 
overall survival (OS) of 6-7 years, while those with high risk disease have a median OS of 
less than 2-3 years, despite therapy (autologous stem-cell transplantation) (Kumar, 2008). 
 
 Stage I  
(Standard risk*) 
Stage II  
(Intermediate risk*) 
Stage III  
(High risk*) 
Durie/Salmon staging system 
(subclassification 
A= normal renal function with 
creatinine<2mg/100ml 
B=abnormal renal function 
with creatinine≥2mg/100ml) 
ALL the following: 
-Hemoglobin (Hb)> 
10g/100ml 
-Serum calcium normal 
(≤12mg/100ml) 
-Normal bone structure 
-Low M proteins 
production 
(IgG<5g/100ml 
IgA<3g/100ml) 
Fitting neither Stage I 
nor Stage III 
ONE or MORE of the 
following: 
-Hb<8,5g/100ml 
-Serum 
calcium≥12mg/100ml 
-Advanced lytic bone 
lesions 
-High M proteins 
production 
(IgG>7g/100ml 
IgA>5g/100ml) 
International Staging System 
(ISS) 
-Serum β2-
microglobulin<3,5mg/L 
-Serum 
albumin≥3,5g/100ml 
Fitting neither Stage I 
nor Stage III 
- Serum β2-
microglobulin>5,5mg/L 
mSMART guidelines(*) -Hyperdiploidy 
-t (11;14) 
-t (6;14) 
-t (4;14) 
-Deletion 13or 
hypodiploidy by 
conventional 
karyotyping 
-17p deletion 
-t (14;16) 
-t (14;20) 
Table 3.1: summarizing scheme of staging criteria used for MM diagnosis. All the systems divide 
the patients in three categories, referred as stage or risk subset (*). 
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3.2 GENETIC ARCHITECTURE AND DISEASE PROGRESSION 
Myeloma is thought to evolve most commonly from asymptomatic MGUS through a 
multistep process that involves both genetic and microenvironment changes (fig. 3.2.1). 
At the cytogenetic level the myeloma genome is very complex, as shown by Chapman and 
colleagues through the massive parallel sequencing of MM patients (Chapman, 2011). 
Many of the genetic lesions that lead to myeloma have been defined. They include 
hyperdiploidy, inherited variations, translocations, deletions, copy number abnormalities, 
mutations and methylation/microRNA abnormalities.  
 
Figure 3.2.1. Initiation and progression of myeloma (modified from Morgan, 2012). MGUS is a 
indolent condition that evolves to myeloma at a rate of 1% per year. Also SMM lacks of symptoms 
while MM displays several clinical features, such as hypercalcemia, anemia, lytic bone lesions and 
impaired renal function. Later in the disease progression, myeloma plasma cells acquire more 
genetic abnormalities and are no longer restrained to growth within the bone marrow. They can be 
found at extramedullary sites as circulating leukemic cells. 
Three genetic loci have been recently described as associated to increased risk of 
developing myeloma: they involve chromosomal regions 2p (gene pairs DNMT3A and 
DTNB), 3p (ULK4 and TRAK1) and 7p (DNAH11 and CDCA7L) (Broderick P., 2012). 
The study of chromosomal translocations that are generated by aberrant class switch 
recombination (CSR) shows that several oncogenes are placed under the control of the 
strong enhancers of the Ig loci, leading to their deregulation. Among them there are cyclin 
D1 (CCND1), CCND3, fibroblast growth factor receptor 3 (FGFR3) and multiple myeloma 
SET domain (MMSET) (Bergsagel, 2005; Gonzalez, 2007). 
Translocations that induce deregulation of the G1/S transition are early molecular 
abnormalities in myeloma, while other CSR-independent translocation occur later in the 
disease progression. The gene typically deregulated by such events is MYC, and this may 
lead to a more aggressive disease phase (Nobuyoshi, 1991). Another common chromosomal 
aberration is the deletion of chromosome 17p, which occur in 8% of cases at presentation, 
and its frequency increases in the later stages of the disease. The key gene at this site is 
thought to be TP53, and its mutations are associated to increased genomic instability and 
poor outcome (Lodé, 2010). 
 
25 
 
3.3 CELLULAR ORIGINS OF MULTIPLE MYELOMA 
Humans have evolved with the constant requirement to resist infections, and antibody 
production by B cells is an important component of this system. As MM is a tumor of 
antibody-producing PCs, it is fundamental to understand how B cells develop. During the 
early B cell differentiation in the BM the variable (V), diversity (D) and joining (J) gene 
segments of the immunoglobulin (Ig) genes are rearranged to generate the primary Ig 
repertoire. Ig heavy chain gene (IGH) rearrangement precedes Ig light chain, and DH to JH 
joining precedes VH to DJH joining. The assembly of a functional IgH-IgL complex on the 
cell surface (the so-called pre B-cell receptor, BCR), allows the B cells to escape apoptosis 
and exit the BM environment and move to secondary lymphoid organs. In the lymph node 
the virgin B cells reach the germinal center (GC), where cells expressing a functional BCR 
undergo affinity maturation in response to antigen-presenting cells (APCs). This process 
requires that the IGH locus undergoes somatic hypermutation (SHM) to produce highly 
specific and avid antibodies and the class switch recombination (CSR), namely the 
mechanism that changes the IgM isotype to IgG-, IgA- or IgE-generating antibodies with 
different functional characteristics (Janeway, 2005). If illegitimate CSR occurs during the 
GC reaction while the cell can still undergo maturation to a memory B cell, it may exit the 
lymph node with an acquired ability to survive and proliferate as a consequence of 
oncogene deregulation. The acquired survival/proliferative ability would allow this 
premalignant clone of PCs to accumulate secondary hits, which will eventually occur in and 
deregulate critical genes, leading to emergence of a malignant myeloma cline in the BM. 
As a result of having undergone the processes of SHM and CSR, the Ig genes in PCs from 
MM patients are characterized by heavily mutated VH  regions and carry isotype-switched 
IGH genes (IgG or IgA) (Bakkus, 1992). Moreover, about 60% of myelomas carry 
translocations targeting the switch regions of the IGH genes locate at chromosome 14q32 
(Bergsagel, 1996). On the basis of these observations, it can be concluded that 
translocations in myeloma constitute early events being responsible for tumor initiation but 
not for complete tumorigenic transformation. This hypothesis is also supported by 
observations that the frequency of translocations in MGUS and MM is similar, but only a 
small number of MGUS patients progresses to myeloma. Several secondary hits are 
acquired by myeloma-propagating cells, leading to the clinically recognized features of the 
disease. (fig. 3.3.1) 
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Figure 3.3.1. MM genesis hypothesis (Gonzalez, 2007). 
 
3.4 THE BONE MARROW MICROENVIRONMENT IN MULTIPLE 
MYELOMA 
The close interaction between malignant cells and the local microenvironment where they 
reside is a feature that MM shares with a broad spectrum of solid tumors and hematological 
neoplasias.  
The bone marrow microenvironment consists of cellular and non-cellular elements. Cell 
components include hematopoietic stem cells (HSCs), progenitor cells, immune cells, 
erythrocytes, BM fibroblast-like stromal cells (BMSCs), vascular endothelial cells, 
osteoclasts and osteoblasts (fig. 3.4.1). The non-cellular elements are represented by 
extracellular matrix (ECM) proteins, such as fibronectin, collagen, laminin and osteopontin. 
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Figure 3.4.1. Interaction between malignant plasma cells and bone marrow in MM (Palumbo, 
2011). The bone marrow niche represent a crowded stage in which the myeloma propagating cells 
have the main role in disease development and are supported by several secondary actors in disease 
progression. As part of the interaction between plasma cells and stromal cells, adhesion is mediated 
by cell-adhesion molecules, such as vascular-cell adhesion molecule 1 (VCAM1) and integrin alpha 4 
(VLA-4). This interaction increases the production of growth factors, such as interleukin- 6 and 
vascular endothelial growth factor (VEGF), which stimulates both plasma cells and angiogenesis. 
The increased osteoclast activity is due to an imbalance in the ratio between receptor activator of 
nuclear factor κB (RANK) and osteoprotegerin (OPG) as a result of enhanced production of RANK 
ligand (RANKL) and reduced production of OPG. Osteoblast activity is also suppressed by the 
production of dickkopf homolog 1 (DKK1) by plasma cells. Moreover, plasma cells can inhibit a key 
transcription factor for osteoblasts, runt-related transcription factor 2, causing a reduction in 
differentiation from precursors to mature osteoblasts. The adhesion of plasma cells to stromal cells 
up-regulates many cytokines with angiogenic activity, in particular interleukin-6 and VEGF. 
Osteoclasts that are activated by stromal cells can also sustain angiogenesis by secreting osteopontin. 
Chromosomal abnormalities can cause overproduction of receptors on myeloma cells. The 1q21 
amplification causes an increase in interleukin-6 receptor and consequently an increase in growth 
mediated by interleukin-6. CCR1 denotes chemokine receptor 1, CD40L (or CD40LG) CD40 ligand, 
FGFR3 fibroblast growth factor receptor 3, HGF hepatocyte growth factor, ICAM1 intercellular 
adhesion molecule 1, IGF1 insulin-like growth factor 1, MIP1α macrophage inflammatory protein 1 
α, MUC1 cell-surface–associated mucin 1, and NF-κB nuclear factor κB. 
 
Once myeloma cells are within the bone marrow, they localize in close proximity to stromal 
cells, forming specialized tumor niche that support plasma cells survival. The direct 
interaction of MM cells with BM microenvironment cells in fact, activate signaling 
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pathway mediating growth, survival, drug resistance and the migration of MM cells 
(Hideshima, 2002a), as well as osteoclastogenesis (Roodman, 2006), angiogenesis (Ribatti, 
2006) and secretion of several soluble factors, such as interleukin 6 (IL-6) (Chauhan, 1996), 
vascular endothelial growth factor (VEGF) (Podar K., 2001), stromal cell-derived factor 1 
(SDF-1) (Hideshima, 2002b) and insulin-like growth factor (IGF1) (Mitsiades, 2004). Both 
homotypic and heterotypic adhesion of MM cells to either BMSCs or ECM are mediated 
through several adhesion molecules, i.e. CD44, very late antigen 4 (VLA-4), VLA-5, 
intracellular adhesion molecule (ICAM-1), NCAM, syndecan 1 and MPC-1.  
Excessive activation of Notch pathway has been described in MM, resulting in increased 
secretion of MM plasma cell survival factors IL-6 and VEGF (Houde, 2004). The Notch 
role in MM will be deeply discussed afterwards. 
 
In the following paragraphs is reported a focus on three key elements of the interaction 
between myeloma and BM niche: the osteoclastogenesis, the adhesion molecules and the 
soluble factors and their receptors. 
 
3.4.1 Osteoclastogenesis 
The cellular interplay between MM cells and BM microenvironment mediates the 
formation of bone lesions. MM growth is associated with increased numbers of osteoclasts 
and suppression of osteoblastogenesis in areas adjacent to tumor foci. These effects are 
frequently described to establish a “vicious cycle” between tumor cells and surrounding 
environment: myeloma induces osteoclastogenesis and osteoclasts induce myeloma growth 
(Sezer, 2009). The molecular mechanisms by which myeloma cells stimulates osteoclasts 
activity are multifactorial and involve osteoclasts differentiation and survival factors that 
are produced by microenvironmental cells and myeloma cells. Several osteoclastogenic 
factors have been described to be involved in MM-induced osteoclasts activity: receptor 
activator of NF-κB ligand (RANKL), inflammatory protein-1 alpha (MIP-1α) , SDF-1α, IL-
3, IL-6 and TNFα. 
RANKL is a member of the tumor necrosis factor superfamily and is produced mainly by 
osteoblastic lineage cells and stromal cells. Its receptor, RANK, is expressed on the surface 
of osteoclasts precursors and mature osteoclasts. RANKL indices differentiation, formation, 
fusion and survival of preosteoclasts. Osteoprotegerin (OPG) is a decoy receptor antagonist 
for RANKL, mainly secreted by osteoblastic lineage and stromal cells. MM cells induce 
stromal cells to upregulate RANKL and to downregulate OPG (Giuliani, 2001). A balanced 
RANKL/OPG ratio is essential for normal bone turn over: Qiang and colleagues 
demonstrated that myeloma cell production of Wnt antagonist dickkopf 1 (DKK1) 
abrogates the canonical Wnt signaling to commit immature cells to osteoblastogenesis, 
ultimately increasing RANKL/OPG ratios, resulting in activation of osteoclasts and bone 
resorption (Qiang, 2008).  
MIP-1α belongs to the RANTES family of chemokines and is chemotactic for osteoclasts 
precursors and promotes osteoclastogenesis by increasing production of RANKL and IL-6 
(Choi, 2001). In addition to osteoclastogenic factor produced by MM cells, it has been 
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reported that myeloma cells form themselves multinucleated cells capable of bone 
resorption (Silvestris, 2009). SDF-1α is directly responsible for chemotactic recruitment, 
development and survival of human osteoclasts (Wright, 2005). Moreover, elevated serum 
levels of SDF-1α are associated with osteolytic bone lesions and increased osteoclasts 
activity in MM patients (Zannettino, 2005). 
Interestingly, multiple myeloma cell–osteoclast interactions produces the up-regulation of 
the enzyme Chondroitin synthase 1 (CHSY1), involved in the synthesis of chondroitin 
sulfate which  plays structural roles in cartilage and bone; CHSY1, induces Notch 
signalling and survival of multiple myeloma cells, and therefore represents a novel 
therapeutic target (Yin, 2005). 
As mentioned above, osteoclastogenesis and osteoblastogenesis in the normal bone are 
finely balanced, but this equilibrium is disrupted in MM: mesenchymal cells (MSCs) 
isolated from MM patients are genetically and phenotypically abnormal, and have impaired 
osteogenic potential (Corre, 2007).  
 
3.4.2 The adhesion molecules 
Adhesion molecules on MM cells were identified about two decades ago, and specific role 
in their adhesive interaction with the ECM were attributed to integrins (Uchiyama, 1992). 
MM cells exhibit preferred adhesion to several ECM constituents, including laminin, 
collagens and fibronectin (FN), via β1 integrin-mediated adhesion. 
Integrins are heterodimeric cell surface receptors that mediate adhesion to the ECM and 
immunoglobulin superfamily molecules. At least 24 distinct integrins heterodimers are 
formed by the combination of 18 α-subunits and 8 β-subunits. They are essentially 
expressed by all cell types, including cancer cells (Desgrollier, 2010). A wide range of 
integrins is expressed by MM cell lines and primary MM cells, but about their specific 
functional roles still little is known. The best characterized are α4, α5, αv and the β1 
subunits. 
The predominant cellular receptor for FN is α5β1 integrin, also called VLA-5 or CD49e, 
which is expressed by normal PCs and in the initial stages of MM. Conversely, with the 
disease progression and on extramedullary MM cells there is a significant down-regulation 
of this integrin (Pellat-Deceunynck, 1995). In contrast with the monogamy of the 
interactions between integrin α5β1 and FN, the α4 subunit can form a heterodimer with β1 
subunit and bind FN or vascular cell adhesion molecule 1 (VCAM-1), or pair with the β7 
subunit to bind mucosal addressin call adhesion molecule (MAdCAM-1). Unlike the 
expression pattern of α5β1 integrin, α4β1 integrin (also referred as VLA-4 or CD49d) is 
expressed by all plasma cells, both normal and malignant (Pals, 2007), and it was found to 
be over-expressed in drug-resistant MM cells (Damiano, 1999). The β7 subunit can pair 
with αE subunit to mediate the adhesion of MM cells to BM stromal cells, via E-cadherin 
binding. The activity of α4β1 integrin is regulated both by ligand binding and by 
conformational changes induced by inside-out signaling (Chigaev, 2009). MM derived cell 
lines express α4β1 integrin, albeit al low/moderate activation status, and their cell-surface 
levels can be up-regulated by cytokines, e.g. TNFα (Hideshima, 2001) (fig. 3.4.2). 
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Figure 3.4.2. Adhesion molecules expressed in myeloma cells (Katz, 2010) Integrins are the major 
receptors of the various ECM components of the BM, as well as of surface molecules of stromal cells. 
The levels of expression of these adhesion molecules are regulated by intracellular elements, (e.g. 
oncogenes), by extracellular factors (e.g. growth factors) and microenvironmental conditions (e.g. 
hypoxia)  
Others cell-surface molecules need to be taken into consideration while describing MM 
cells interactions with the bone marrow niche: one of the specific surface markers of MM 
cells is CD138, also identified as syndecan-1. Syndecans are type I transmembrane 
proteglycans consisting of a core protein to which are covalently attached long 
glycosaminoglycans (Sanderson, 2002). Through its cytoplasmatic tail, CD138 signaling 
converge on focal adhesion formation, while with the extracellular portion binds directly to 
ECM proteins (e.g. FN) (Morgan, 2012). 
Adhesion molecules are responsible for the development of MM cells resistance to front-
line chemotherapeutic drugs, such as melphalan (an alkylating agent) and doxorubicin (an 
anthracycline), thus leading to treatment failure. This phenomenon is referred as cell 
adhesion mediated drug resistance (CAM-DR), and it suppresses drug-induced apoptosis 
(Hazlehurst, 2001). As reported by Damiano, drug selection of either RPMI-8266 or U-266 
myeloma cell line changed the integrins expression profile and increased cellular adhesion 
to FN through VLA-4 overexpression. This cell adhesion mediated drug resistance, which 
was not due to upregulation of anti-apoptotic Bcl-2 family members. (Damiano, 1999). The 
proteasome inhibitor bortezomib was shown to overcome CAM-DR by selectively 
downregulating VLA-4 expression in MM cells (Noborio-Hatano, 2009).  
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3.4.3 Soluble factors and their receptors 
Since MM mainly progresses in the bone marrow, signals from this microenvironment play 
a critical role in the maintaining plasma cell growth, survival, migration, drug resistance 
and angiogenesis Reciprocal interactions between PCs and BM cells, namely HSCs, 
stromal cells, osteoblasts, osteoclasts, vascular endothelial cells and immune cells are 
mediated by an array of cytokines and receptors. PCs in the BM secrete tumor necrosis 
factor-α (TNFα), transforming growth factor-β (TGF-β), VEGF, Angiopoietin-1, FGF-2 
and matrix metalloproteases (MMPs). Moreover, the cell-cell interactions mediated by 
adhesion molecules between PCs and BM cell trigger transcription and secretion by the 
latter of cytokines, such as IL-6, VEGF, SDF-1 (CXCL12), MCP-1 (CCL2) Hepatocyte 
growth factor-scatter factor (HGF-SF) and IGF-1 (Ribatti, 2006; Hideshima, 2001; Barillé, 
1997; Dankbar, 2000; Ferlin, 2000; Alsayed, 2007). 
The first cytokine described that placed the focus on BMSCs-MM interplay was probably 
IL-6: in 90’s it was known that IL-6 induces in vitro growth of freshly isolated MM cells 
and that MM cells express the IL-6 receptor (IL-6R). Moreover, several MM cell lines have 
been described to be responsive and produce IL-6, thus leading to hypothesize an autocrine 
pattern. 
In the same years, many studies showed that BMSCs are the major source of IL-6 and that, 
although all human MM-derived cell lines express IL-6R mRNA, only a subset express IL-
6 mRNA. In 1996, Chauhan and colleagues finally showed that adhesion of MM cell lines 
to BMSCs and BMSC lines resulted in significant increase in IL-6 secretion by BMSCs, 
thus supporting tumor growth. Noteworthy, through gene reporter assays, they also indicate 
involvement of NF-κB in regulation of IL-6 transcription triggered in BMSCs (Chauhan, 
1996). Various soluble factors have been shown to mediate IL-6 secretion by BMSCs or 
MM cells, e.g. IL-1α, IL-1β, TNFα and VEGF. In MM, VEGF is expressed and secreted by 
tumor cells as well as BMSCs. It induces proliferation through Raf-1-MEK-extracellular-
signal-regulated protein kinase (ERK) pathway, it triggers migration of human MM cells 
through a protein kinase C (PKC)-dependent cascade (Podar, 2001) and it stimulates the 
expression of IL-6 by microvascular endothelial cells and BMSCs (Dankbar, 2000). 
TNFα is known to be a potent mediator of inflammation and bone resorption expressed by 
BMSCs and PCs from myeloma patients. Several studies confirmed a central role for this 
cytokine in the growth and survival of MM cells in the BM milieu, given that TNFα 
induces proliferation expression of ICAM-1, VCAM-1 and VLA-4 and MAPK/ERK 
activation in MM cells, while IL-6 secretion, NF-κB activation and expression of ICAM-1 
and VCAM-1 in BMSCs (Hideshima, 2001). 
HGF-SF is a pleiotropic cytokine that induces complex biological responses in target cells, 
including motility and growth. Its biological effects are transduced via the transmembrane 
tyrosine kinase Met, while syndecan-1 (CD138) strongly promotes HGF-induced signaling 
through Met, thereby acting as a co-receptor (Derksen, 2002). MM cell lines and BM 
plasma cells express both HGF-SF and its receptor Met (Borset, 1996). 
MM is a tumor with a high capacity to destroy the bone matrix thanks to matrix 
metalloproteases (MMPs) expression (Barillé, 1997). MMPs are a family of zinc-dependent 
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endopeptidases with proteolytic activity for a large range of components of the extracellular 
matrix (ECM). These enzymes are involved in physiologic ECM turn over, bone 
remodeling, wound healing and angiogenesis, as well as in several pathologic processes, 
such as rheumatoid arthritis and tumor invasion. Human myeloma cells secrete 
constitutively MMP-9, while BMSCs secrete MMP-1 and MMP-2, thus supporting the 
spreading of MM cells inside and outside the BM (fig. 3.4.3). 
Finally, SDF-1 (CXCL-12) and its receptor, CXCR4, play a fundamental role in MM 
pathogenesis, because they mediate the MM cell homing to the BM. Chemokines influence 
migration, survival and other actions of HSCs, immune cells and cancer cells; for this 
reason, the chemokine system and in particular SDF-1/ CXCR4 axis will be deeply 
discussed in the following paragraph. 
 
 
Figure 3.4.3. Model for the role of chemokines in myeloma tumor progression in bone. MCP-1 and 
SDF-1 produced by marrow stromal cells/osteoblasts attract myeloma cells to bone. Myeloma cells 
then bind to marrow stromal cells through VCAM-1 (Step 1). Marrow stromal cells then increase 
expression of TNF-α, MCP-1, IL-8, and IL-6. Myeloma cells then increase production of MIP-1α and 
IL-3, which stimulate their growth (Step 2). These cytokines and chemokines enhance myeloma cell 
survival and growth and increase angiogenesis. The increased expression of RANKL, IL-3, IL-8, 
MCP-1, IL-6, and MIP-1α induce osteoclast formation and bone destruction (Step 3). 
 
3.5 MM THERAPY 
Initial treatment of multiple myeloma depends on the patient’s age and co-morbidities. In 
recent years, high-dose chemotherapy with autologous hematopoietic stem-cell 
transplantation has become the preferred treatment for patients under the age of 65. Prior to 
stem-cell transplantation, these patients receive an initial course of “induction 
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chemotherapy” comprising of cyclophosphamide and a white blood cell stimulating drug: it 
was shown that chemotherapy treatment induces hematopoietic stem-cell migration from 
the BM to the peripheral blood vessels; then blood-forming stem cells are removed from 
the patient's blood by a process called leukapheresis and are preserved. 
After the high-dose chemotherapy, which is toxic for BM, stem cells are given back to the 
patient to reconstitute its BM. It is not curative, but does prolong overall survival and 
complete remission. Also allogeneic stem cell transplantation, of a healthy person’s stem 
cells into the affected patient, has the potential for a cure, but is only available to a small 
percentage of patients. 
 
The MM patient can receive treatment with a variety of agents, including chemotherapy, 
corticosteroids, immunomodulating agents, proteasome inhibitor, or a combination thereof. 
Novel biologically based treatments target not only the MM cell, but also MM cell-host 
interactions and the BM microenvironment (fig. 3.5.1). 
Category of drugs used in MM therapy: 
Immunomodulatory Drugs 
Thalidomide is a derivative of glutamic acid. Thalidomide’s mechanism of action in MM is 
not fully understood. Proposed mechanism(s) include the inhibition of TNF-α production, 
prevention of free-radical-mediated DNA damage, suppression of angiogenesis by blocking 
the angiogenic growth factors basic fibroblast growth factor (bFGF) and/or VEGF, 
induction of apoptosis or G1 growth arrest in drug resistant MM cells and modulation the 
binding of MM cells to BMSCs trough the alteration of cellular adhesion molecules 
expression. Thalidomide and its derivatives also block the induction of cytokine (such as 
IGF1, IL-6 and VEGF) secretion that is triggered by MM cell binding to BMSCs, and 
augment natural-killer-cell and T-cell activity against myeloma cells by stimulating their 
proliferation and the secretion of interleukin 2 and interferon-γ. Finally, Thalidomide may 
also inhibit the activity NF-κB  and the enzymes cyclo-oxygenase -1 and -2.  Side effects - 
most importantly, constipation, somnolence, teratogenicity and neuropathy - are typically 
dose dependent but they were not observed in novel immunomodulatory drugs, such as 
Lenalidomide. 
Proteasome Inhibitors 
Bortezomib is a first-in-class proteasome inhibitor. Bortezomib targets the 26S proteasome, 
a multicatalytic proteinase complex involved in degradation of cyclin and cyclin-dependent 
kinase inhibitor (CKI) proteins, thereby regulating cell-cycle progression. 
Bortezomib inhibits NF-κB  activation and nuclear translocation by protecting from 26S 
degradation its inhibitor IκBα, a protein that is constitutively bound to cytosolic NF-κB. In 
fact, degradation of IκBα by proteasome activates NF-κB , which up-regulates transcription 
of proteins that promote cell survival and growth, modulates MM cell-adhesion-induced 
cytokine transcription and secretion in BMSCs, decreases apoptosis susceptibility, 
influences the expression of adhesion molecules on BMSCs/ MM cells and their related 
binding, and induces drug resistance in myeloma cells. 
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Bortezomib also induces apoptosis through caspase-8 and -9 activation, inhibits IL-6 and 
BMSC–MM cell adherence-induced p42/p44 MAPK phosphorylation and proliferation in 
MM cells Bortezomib not only targets the myeloma cell, but also acts in the bone marrow 
microenvironment by inhibiting the binding of myeloma cells to bone marrow stromal cells 
and bone marrow-triggered angiogenesis. 
Alkylating agents 
Melphalan is an alkylating drug that acts adding an alkyl group to DNA, inducing DNA 
damage and duplication arrest. Since cancer cells grow faster than normal cells, they die off 
more quickly, reducing the number of cancerous cells. Unfortunately, the alkylating 
antineoplastic agent doesn't discriminate between healthy cells and cancerous ones giving 
these drugs significant side effects. 
Cyclophosphamide is a nitrogen mustard alkylating agent, the main effect of 
cyclophosphamide is due to its metabolite phosphoramide mustard which forms DNA 
crosslinks both between and within DNA strands at guanine N-7 positions (known as 
interstrand and intrastrand crosslinkages, respectively). This is irreversible and leads to cell 
death. Cyclophosphamide also decreases the immune system's response to various diseases 
and conditions 
Corticosteroids 
Dexamethasone, prednisone, prednisolone and other synthetic steroids are useful in 
myeloma treatment because they act as anti-inflammatory and immunosuppressant drugs 
and can stop white blood cells from traveling to areas where cancerous myeloma cells are 
causing damage. This decreases the amount of swelling or inflammation in those areas and 
relieves associated pain and pressure. Recent studies show that in high doses, 
dexamethasone can kill myeloma cells. 
Anthracycline antibiotics  
Doxorubicin works by interacting with DNA by intercalation and inhibition of 
macromolecular biosynthesis. This inhibits the progression of the enzyme topoisomerase II, 
which relaxes supercoils in DNA for transcription. Doxorubicin stabilizes the 
topoisomerase II complex after it has broken the DNA chain for replication, preventing the 
DNA double helix from being resealed and thereby stopping the process of replication. 
Topoisomerase inhibitors 
Mitoxantrone is an anthracenedione antineoplastic agent. It is a type II topoisomerase 
inhibitor and it disrupt DNA synthesis and DNA repair in both healthy and cancer cells 
trough intercalation. It also acs as an immuno-modulator that inhibits T and B-cell activity. 
Mitotic inhibitor 
Vincristine is a mitotic inhibitor drug that acts binding to tubulin dimers and inhibiting 
assembly of microtubule structures. Disruption of the microtubules arrests mitosis in 
metaphase. Therefore, the mitotic inhibitors affect all rapidly dividing cell types including 
cancer cells, but also healthy cells. 
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The most common induction regimens used today are 
thalidomide/dexamethasone,/bortezomib based regimens, and lenalidomide/dexamethasone 
followed by the autologous hematopoietic stem-cell transplantation. 
Patients over age 65 and patients with significant concurrent illness often cannot tolerate 
stem cell transplantation. For these patients, the standard of care has been combination 
chemotherapy with melphalan / prednisone/ bortezomib or melphalan/prednisone/ 
lenalidomide: recent studies among this population suggest improved outcomes with this 
chemotherapy regimens.  
In addition to direct treatment of the plasma cell proliferation, bisphosphonates (e.g. 
pamidronate or zoledronic acid) are routinely administered to prevent fractures; they have 
also been observed to have direct anti-tumor effect even in patients without known skeletal 
disease. 
 
Other therapies in early development are: ABT-737 (Bcl-2 antagonist) - TRAIL/APO2L 
(member of the TNF superfamily of death-inducing ligands) - 2Methoxyestradiol (potent 
antitumour and anti-angiogenic natural metabolite) - and several inhibitors as of histone 
deacetylas, farnesyltransferase, VEGF and Notch which are involved in the blocking of 
interaction, trafficking and cross-talk between BM tumoral cells in MM (Palumbo, 2011; 
Schwartz, 2008; Kyle, 2004; Hideshima, 2002b). 
 
 
Figure 3.5.1. Proposed Mechanism of Action of Drugs to Target the Myeloma Cell and 
Components of the Bone Marrow Microenvironment (Kyle, 2004). In myeloma cells, alkylating 
agents, corticosteroids, and bortezomib inhibit cell growth and induce apoptosis. The effect of 
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bortezomib on myeloma cells is mediated in part by the inhibition of nuclear factor-kB. Thalidomide 
and bortezomib inhibit the interaction between myeloma cells and stromal cells as well as the 
production of cytokines such as tumor necrosis factor a and interleukin-6. Thalidomide inhibits 
angiogenesis and stimulates the immunesurveillance properties of T cells and natural killer cells. 
Solid arrows indicate stimulation or secretion and dashed arrows inhibition. 
 
3.6 DRUG-RESISTANCE MECHANISMS IN MULTIPLE MYELOMA 
Multiple myeloma cells manifest intrinsic genetic mechanisms of drug resistance, (owing, 
for example, to p53 mutations), or can acquire resistance following exposure to 
conventional chemotherapeutic treatment (for example, through overexpression of the P-
glycoprotein that can confer multidrug resistance following exposure to alkylating agents or 
anthracyclines). In addition, binding of multiple myeloma cells to extracellular matrix 
proteins induces cell-adhesion-mediated drug resistance (CAMDR) to conventional 
chemotherapy (for example, adhesion of tumour cells to fibronectin triggers upregulation of 
p27 and induces nuclear factor-κB (NFκB) activation leading to CAMDR). Moreover, 
multiple myeloma cells in the bone marrow, both by virtue of cell–cell contact with 
accessory cells (bone marrow stromal cells (BMSCs), osteoclasts, osteoblasts and 
endothelial cells) and secretion of growth factors (TGF-β) further induce transcription and 
secretion of cytokines, which in turn confer drug resistance (for example, interleukin 6 
secretion by BMSCs, osteoclasts and endothelial cells abrogates the apoptosis triggered by 
dexamethasone). Although the precise mechanism is still to be clarified, new therapeutic 
agents, such as bortezomib, can overcome intrinsic drug resistance, as well as CAMDR and 
the protective effects of cytokines, and induce multiple myeloma cell cytotoxicity in the 
bone marrow milieu. These agents can also overcome clinical drug resistance to 
conventional and high-dose chemotherapies. 
IL-6 confers resistance to dexamethasone through the activation of JAK/STAT signalling 
and the upregulation of the antiapoptotic proteins BCL-XL and myeloid cell leukaemia 
sequence-1(MCL1). In addition, IL-6 activates SRC-homology tyrosine phosphatase 2 
(SHP2), which blocks dexamethasone induced activation of RAFTK and apoptosis. Both 
IL-6 and IGF1 inhibit the drug-induced apoptosis of MM cells through PI3K/AKT 
signalling and NF-κB activation, with the downstream induction of intracellular inhibitors 
of apoptosis (IAPs) including FLICE inhibitory protein (FLIP), survivin, cellular inhibitor 
of apoptosis-2 (cIAP2), A1/BFL1 and X-linked inhibitor of apoptosis protein (XIAP) 
(Hideshima, 2007). 
 
 
3.7 NOTCH AND MULTIPLE MYELOMA 
Notch deregulation is involved in several malignancies behaving as either an oncogene or a 
tumor suppressor, depending upon cellular context. Notch signaling deregulation 
characterizes different hematopoietic malignancies. Among these, multiple myeloma (MM) 
is associated to a deregulation of Notch signaling driven by the overexpression of its ligand 
Jagged2 by tumor cells. Recently, several studies focused on the role of Notch pathway in 
MM. The pathological nature of MM lesions makes it a peculiar hematological tumor, 
strongly depending on the interaction with the microenvironment. Evidences so far 
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available indicate a very complex picture, which involves Notch in the regulation of the 
interactions between MM plasma cells and the bone marrow niche. 
As mentioned above, Notch activation is tightly controlled during hematopoietic lineage 
differentiation and under physiologic conditions, hematopoietic stem cells carry Notch 
receptors and receive signals from Notch ligands expressed by BM stromal cells, providing 
signals for stem cell self-renewal, survival and differentiation. This delicate mechanism is 
exploited by malignant plasma cells which establish complex interactions with BM stromal 
cells through direct cell-cell contact and secretion of soluble mediators (fig. 3.7.1), thus 
leading to MM cell proliferation, chemoresistance and bone disease. Despite major 
advances in the treatment of MM in recent years, it still remains largely incurable and the 
failure of the current therapeutic strategies is mainly due to the MM cells’ ability to 
deregulate the complex BM microenvironment. 
Notch receptors (Notch 1, 2 and 3) are expressed on primary MM cells, BMSCs and 
osteoclasts (OCL), while Notch ligands (Jagged-1 and Jagged-2) are expressed on MM, 
BMSCs and macrophages, thus they are able to activate Notch signaling through homotypic 
as well as heterotypic interactions in MM cells. 
In these deregulated interaction, Jagged-2 plays a central role as its over-expression was 
observed in MM patients. Jagged-2 overexpression is caused by epigenetic deregulations 
including promoter hypomethylation (Houde, 2004) constitutive core promoter acetylation, 
due to reduced levels of the SMRT co-repressor (Ghoshal, 2009). Jagged-2 deregulation 
can occur at post-transcriptional level, involving the over-expression of Jagged-2-specific 
ubiquitin-ligase Skeleotrophin (Takeuchi, 2005). 
Jagged-2 overexpression is an early event; it is present in MGUS patients as well as in MM 
ones, whereas it is absent in non-MM samples. Noticeably, Jagged-2 expression levels 
increase with disease stage (Houde, 2004). 
MM cells can autonomously activate Notch signaling through homotypic interactions since 
they simultaneously express Notch-1, -2 and -3 receptors and their ligands; but, although 
Notch ligands can be detected on MM cells, they are abundantly expressed by stromal cells 
and macrophages (Fukushima, 2008); consequently, these BM-residing cells can activate 
Notch signaling in MM cells through heterotypic interactions . 
As reported by Houde et. al, also Jagged-expressing MM cells can activate Notch signal in 
stromal cells, leading to increased secretion of IL-6, VEGF and IGF-1 by the stromal cells 
(Houde, 2004). 
Indeed, the co-culture of MM cell line with DLL-1+ stromal cells promotes MM 
clonogenic growth in vitro and also accelerates MM development in vivo (Xu, 2012). 
Noteworthy, mammalian Notch-1 signaling promotes β1 integrins activation, thus 
modulating the main adhesion molecules that mediate myeloma-stromal cells interplay 
(Hodkinson, 2007). Besides the adhesion molecules, Notch pathway also controls the 
expression and functions of several chemokine receptors, such as CXCR4 in MM 
(Mirandola, 2011b).  
In the last few years, the importance of Notch signaling in osteoblasts (OBs) and osteoclasts 
(OCs) has emerged: Notch overexpression blocks the maturation of OB precursors by 
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opposing canonical Wnt/ β-catenin signaling (Zanotti, 2008). On the other side, a study 
reported that Notch-2 and Jagged-1 are up-regulated in OC precursors during RANKL-
induced osteoclastogenesis and that Notch-2 modulates the RANK signaling in association 
with NF-κB (Fukishima, 2008). Interestingly, in OCs-MM cells co-cultures, Notch 
downstream target gene Hes-1 was found upregulated in OCs, as well as the tartrate 
resistant acid phosphatase-5 gene (TRAP), which correlates with OC function and serves as 
a specific marker of OC activity (Schwarzer, 2008). Taken together, these evidences 
suggest that the increased Notch signaling contributes to MM cell-dependent activation of 
OC through direct cell–cell contact. 
The outcomes of Notch activation on tumor MM cells are apoptosis inhibition (Nefedova, 
2004; Schwarzer, 2008) and decreased sensitivity to chemotherapeutics (Nefedova, 2004); 
for this reason, inhibition of this pathway was proposed as an emerging strategy for cancer 
treatment. As described above, Notch activation requires two consecutive proteolytic 
cleavage steps, followed by the active NICD translocation to the nucleus. So far, blocking 
the final intra-membraneous cleavage mediated by the γ-secretase complex has been shown 
as a successful strategy. Nefedova and colleagues first reported that the pharmacologic 
inhibition of Notch signaling may enhance the effect of chemotherapy in MM: gamma-
secretase inhibitors (GSI) treatment induces apoptosis of MM cells in vitro, and enhances 
drug sensitivity in vivo (Nefedova, 2008a; Nefedova, 2008b). MM cells reside primarily in 
the BM, where they interact with components of the BM microenvironment, including 
stromal cells. During the last 20 years, increasing evidences supported the idea that the 
interplay between tumor cells and BM, through the BM niche, has profound effects on 
growth, survival and chemo-sensitivity of malignant cells. As claimed by the previous 
paragraphs, Notch pathway is among the main factors that mediate this interaction. 
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Figure 3.7.1. Interaction between MM cells and  OCL and BMSC. Roles of Notch receptors and 
ligands in the vicious circle are established by MM cells and the bone marrow microenvironment 
interactions. Notch signaling is activated by Jagged-1,2 ligands expressed by MM cells and bone 
marrow stroma cells (BMSCs). NICD triggers proliferative and anti-apoptotic signals in malignant 
cells. MM cell-expressed Jagged-1,2 ligands also prompt Notch signaling in BMSCs and osteoclasts 
(OCLs). Upon Notch stimulation, BMSC secretes MM growth factors, such as IL-6, VEGF and IGF; 
further, it is possible that Notch receptor also control the expression of IL-8, MMPs and SDF1 by 
BMSCs, contributing to tumor burden. Particularly, SDF1 activates the chemokine receptor CXCR4 
in MM cells, promoting their proliferation and recruitment to the bone marrow, while MMPs 
contribute to bone lesions and MM cell growth. MM-driven Notch activation in OCL stimulates bone 
resorption mechanisms. Although the main factor controlling CCR6 expression in OCLs is BMSC-
derived RANK ligand (RANK-L), the possibility exists that Notch1 activation increases CCR6 levels, 
that in turn, mediates OCL recruitment to osteolysis sites and OCL activation. More details are in the 
text. 
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4. CHEMOKINE SYSTEM 
 
4.1 STRUCTURE AND FUNCTION OF CHEMOKINES AND CHEMOKINE 
RECEPTORS 
Chemokines are a family of roughly 50 small cytokines (soluble secreted proteins of 8-14 
kDa), named for chemoattractant activities. Their current nomenclature is based on the 
arrangement of the first two of four conserved cysteine residues near the N-terminus  that 
are key to forming their  tertiary structure. Subfamily members are classified in CXC-, CC-, 
XC and CX3C motifs. They bind to specific G-protein coupled seven-span transmembrane 
receptors (GPCRs) (Broxmeyer, 2008) (fig. 4.1.1) 
 
 
Figure 4.1.1. Leukocyte expression and ligand specificity of chemokine receptors. (Mantovani, 
2004) 
 
The genes encoding  chemokines are clustered in close physical proximity to each other and 
have a high degree of homology. The receptors for CXC chemokines (CXCR) are 
characterized by amino acid identity between 36% and 77%, while the CC chemokine 
receptor (CCR) have between 46% and 89% amino acid identity. This could indicate that 
these genes have arisen by gene duplication and divergent evolution.  
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The chemokines physiology is still not completely clear because of the ability of a receptor 
to bind different chemokines and of one chemokine to bind different receptors. The 
consequence of this system redundancy is that each chemokine may recruit more cell types 
that express different receptors and each cell can respond to multiple chemotactic stimuli 
even if they express only one receptor; for these reasons the chemokine systems is less 
influenced by single-gene mutations. 
These proteins exert their biological effects by interacting with G protein-
linked transmembrane receptors called chemokine receptors, that are selectively found on 
the surfaces of their target cells. Approximately 19 different chemokine receptors have been 
characterized to date, which are divided into four families depending on the type of 
chemokine they bind. Chemokine receptors are 7-α-helix transmembrane metabolotropic 
receptors (fig. 4.1.2) comprising of a short N-terminal end involved in ligand binding, 
seven helical transmembrane domains with three intracellular and 
three extracellular hydrophilic loops and an intracellular C-terminus 
containing serine and threonine residues. 
Following binding of the chemokine ligand, chemokine receptors associate with G-proteins, 
allowing the dissociation of the different G protein subunits: 
• the Gβγ subunit activates the  phospholipase C(PLC) which cleaves a molecule 
of phosphatidylinositol (4,5)-bisphosphate (PIP2) into two second messenger Inositol 
triphosphate (IP3) and diacylglycerol (DAG); DAG activates the  protein kinase 
C (PKC), and IP3 triggers the release of calcium from intracellular stores. These events 
promote many signaling cascades (such as the MAP kinase pathway) that generate 
responses like chemotaxis, degranulation, release of superoxide anions and changes in 
the avidity of cell adhesion molecules called integrins within the cell harbouring the 
chemokine receptor. 
• both Gβγ and Gα subunits activate PI3 kinase (PI3K) leads to phosphorylation of 
several focal adhesion components, such as focal adhesion kinase (FAK), paxilin and 
Crk. 
• The subunit Gα directly activates the protein tyrosine kinase (PTK), which 
phosphorylates serine and threonine residues in the cytoplasmatic tail of the chemokine 
receptor, thus uncoupling the G-protein and enabling high affinity interactions with β-
arrestin, which acts as a scaffold, targeting the receptor for internalization and 
degradation (Bennett, 2011) (fig. 4.1.3). 
  
Chemokine secretion occurs in a variety of cell types: some chemokines are considered 
homeostatic (constitutive), they are produced and secreted without any need to stimulate 
their source cells and are involved in controlling the migration of cells during normal 
processes of tissue maintenance or development, while others are considered pro-
inflammatory (inducible) and can be induced during an immune response to recruit cells of 
the immune system to a site of infection, 
The major role of homeostatic chemokines is to act as a chemoattractant to guide the 
migration of cells (fig. 4.1.4). Cells that are attracted by chemokines follow a signal of 
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increasing chemokine concentration towards the source of the chemokine. Some 
chemokines control cells of the immune system during processes of immune surveillance, 
such as directing lymphocytes to the lymph nodes so they can screen for invasion of 
pathogens by interacting with antigen-presenting cells residing in these tissues. Some 
chemokines have roles in development; they promote angiogenesis (the growth of 
new blood vessels), or guide cells to tissues that provide specific signals critical for cellular 
maturation.  
The inflammatory  chemokines are released from a wide variety of cells in response 
to bacterial infection, viruses and agents that cause physical damage. Their release is often 
stimulated by pro-inflammatory cytokines such as interleukin 1 (IL-1) and they function 
mainly as chemoattractants for leukocytes, recruiting monocytes, neutrophils and other 
effector cells from the blood to sites of infection or tissue damage. Certain inflammatory 
chemokines activate cells to initiate an immune response (Mantovani, 2004; Fernandez, 
2002; Laing, 2004; Murdoch, 2000). 
 
Thus, chemokine-mediate signals induce different and frequently redundant effects such as 
chemotaxis, gene transcription, survival or mitogen signals, cytoskeleton modification, 
enzyme secretion, oxygen radicals production, expression of adhesion molecules (Teicher, 
2010). 
It is now accepted that GPCRs not only operate as monomers, but can also function as 
multimers regulated by allosteric mechanisms (Vila-Coro, 1999). Chemokine receptor 
dimers seem to be constitutively formed and ligand binding stabilizes or reorganizes pre-
existing complexes. CXCR4 has been described to form homodimers or heterodimers 
CXCR4/CCR5 and CXCR4/CXCR7. 
 
 
Figure 4.1.2. Structure of a chemokine receptor. 
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Fig.4.1.3 Chemokine receptor signalling in migration and survival/proliferation (O'Hayre, 2008) 
One of the first events of cell migration involves cell polarization in response to a chemoattractant, 
whereby some receptors and signalling molecules localize toward the source of the chemoattractant, 
termed the leading edge, while other molecules distribute away at the trailing edge. This process 
occurs via chemokine:receptor signalling through the class IB PI3Kγ, which activates Rac and 
subsequently PAK (p21-activated kinase). Protrusion of the leading edge to move in the direction of 
the chemoattractant is mediated by actin polymerization and focal adhesions activated as chemokines 
bind to their receptors. Gi-dependent signalling through PI3K and various protein tyrosine kinases 
induces the activation of Akt, Rac and Cdc42, which lead to downstream F-actin polymerization. At 
the trailing edge, activation of ROCK (Rho-associated kinase) downstream of Rho is responsible for 
actomyosin contraction at the rear so the cell can progress forward. Calcium release and PKC 
activation downstream of PLC can also play important roles in mediating adhesion events. Activation 
of FAK, pyk2 (proline-rich tyrosine kinase 2 or FAK-related tyrosine kinase), and other tyrosine 
kinases are also important in this process. FAK activation is important in establishing focal 
adhesions and activating other molecules involved in cell movement, such as p130cas, crk and 
paxillin. Integrin receptors that interact with the ECM to mediate cell adhesion, and secreted 
proteases such as MMPs that can aid in migration by degrading the ECM, can also be activated 
downstream of chemokine signalling. As described in more detail in the section on signalling, some 
chemokines, in normal function or in the context of cancer, also activate a variety of survival and 
proliferation pathways. Anti-apoptotic/survival signalling, transcription of growth and proliferation-
related genes, and transcription of MMPs involved in migration and remodelling the 
microenvironment are all transduced downstream from Akt, ERK, PKC and tyrosine kinase (e.g. Src) 
activation. GRK phosphorylation of the C-terminus of chemokine receptors allows β-arrestin to bind, 
leading to receptor desensitization and internalization. However, β-arrestin binding also leads to the 
activation of several proteins including Src, MAPK (ERK, p38, JNK) and PI3K. Clearly, there is a 
large degree of overlap between the upstream signalling molecules underlying these various 
processes, as these pathways are able to elicit a broad spectrum of effects. Note that continuous lines 
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indicate direct activation or inhibition of the downstream molecule, whereas broken lines indicate 
indirect activation.  
 
 
Figure 4.1.4. This is a diagram showing the effect of chemokine concentration gradient on 
chemotaxis direction. The attracted cell moves through the gradient toward the higher concentration 
of chemokine.  
 
4.2 NOTCH AND CHEMOKINES 
Notch signaling positively regulate a number of chemokine receptors. Stimulation of Pax5-/- 
preBI cells with the Notch ligand Delta1 induces CCR4, CCR8 and CXCR6 expression 
(Maerki, 2006); in Langerhans cell development, Delta1 influences CCR6 expression and 
the chemotactic response to CCL3 (Hoshino, 2005). Notch1 controls CCR7, which causes 
T-cell leukemia  central nervous system (CNS) infiltration (Buonamici, 2009). 
In the last years different groups have reported evidences of a connection between the 
Notch pathway and the CXCR4/SDF1α axis. Both Notch pathway and CXCR4 pathway are 
involved in angiogenesis. The Notch signaling pathway plays critical roles in vascular 
development and in tumor-induced angiogenesis. The Notch ligand Delta-like 4 (Dll4) is 
expressed at sites of active angiogenesis and it signals through receptors Notch1 and 
Notch4. Instead, CXCR4 is expressed in endothelial cells, and its ligand SDF1 is a 
chemoattractant for endothelial cells, inducing formation of capillary sprouts (Williams, 
2008).  
Notch signaling regulates the mobilization and homing of endothelial progenitor cells 
(EPC), probably by the dynamic modulation of CXCR4 expression. Notch signaling-
mediated CXCR4 expression is necessary for EPC to participate in vessel formation (Wang, 
2009). 
Notch is involved in the regulation of CXCR4 levels in endothelial cells (Williams, 2008), 
and a  signaling axis from Notch receptor to chemokine receptor CXCR4 was also found to 
be critical in the dendritic cells (DC) differentiation (Wang, 2009). 
At transcriptional level, in the proximal region of the CXCR4 promoter, there is a binding 
site for CBF-1, a member of CSL family, involved in Notch signaling. 
 
4.2 CHEMOKINE SYSTEM AND CANCER 
The role played by chemokines in neoplasia is multifaceted and widely documented (table 
4.2); chemokines and their receptors are able to regulate and direct tumor localization and 
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metastasis, as well to increase neoplastic cells interactions with the extracellular matrix 
(ECM)  and resistance against apoptotic stimuli (Locati, 2002). 
Immune-cell infiltration of tumours — the leukocyte infiltrate — is a characteristic of 
cancer, and many human cancers have a complex chemokine network that influences the 
extent and phenotype of this infiltrate, as well as tumour cell growth, survival, migration 
and angiogenesis (Balkwill, 2003) (fig. 4.2.1).  
The numbers and types of cell that make up the leukocyte infiltrate in tumours are related to 
the local production of chemokines by both the tumour cells and non-malignant stromal 
cells. CC and CXC chemokines, for instance, are important determinants of the macrophage 
and lymphocyte infiltrate in human carcinomas of the breast, cervix and pancreas, as well 
as sarcomas and gliomas (Balkwill, 2001;  Bottazzi, 1983). 
Chemokines contribute to TH2-cell polarization in tumours and to local suppression of TH1-
cell-mediated cellular immune responses, thereby preventing the host immune system from 
destroying the tumour (because polarized TH2 cell responses are generally ineffective 
against tumours and viruses) ( Skinnider, 2002). 
This strategy might help the tumour to subvert the immune system by establishing a 
microenvironment of immune cells and cytokines that suppress any specific anticancer 
responses (Balkwill, 2001;   Skinnider, 2002). 
For example, chronic exposure of the leukocytes to high concentrations of chemokines in 
the tumour microenvironment can activate type-2-macrophages, which release the 
immunosuppressive cytokines interleukin 10 (IL-10) and transforming growth factor-β 
(TGF-β) (Sica, 2000). Type-2 macrophages also release CCL2, which could contribute to 
TH2-polarized immunity (Balkwill, 2001; Gu, 2000). In addition, the tumour 
microenvironment can inhibit the migration and function of DC1 dendritic cells, which 
regulate TH1 differentiation, and this can also suppress specific immune responses.  
In addition to being immunosuppressive, infiltrating leukocytes might contribute to tumour 
progression by producing matrix metalloproteinases (MMPs) as well as growth and 
angiogenic factors (Pollard, 2004; Mantovani, 2002). In fact, CC chemokines, such as 
CCL2, CCL4 and CCL5, induce MMP9 production in macrophages (Robinson, 2002). 
MMPs, including MMP9, are found at higher levels in many cancers and are important in 
ECM remodelling. MMPs that are produced by stromal and tumour cells function together 
to aid tumour cell migration and invasion. 
Infiltrating leukocytes are not the only cells that respond to chemokine gradients in cancers; 
cancer cells themselves can express chemokine receptors and respond to chemokine 
gradients (Muller 2001;  Murphy 2001).  
Malignant cells from different cancer types express different profiles of CC and CXC 
chemokine receptors. However, the chemokine receptor that is most commonly found on 
human and murine cancer cells is the CXC receptor CXCR4. 
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Figure 4.2.1. An inflammatory cytokine induces chemokine production by a tumour cell. A 
macrophage that expresses the corresponding receptor binds the chemokine and undergoes rapid 
cytoskeletal rearrangement. This is followed by induction of a transcriptional programme that 
favours cell migration — for example, induction of matrix metalloproteinases (MMPs) — and cell 
survival. The cell migrates towards a higher concentration of chemokine. As the chemokine 
concentration increases, the chemokine receptor can be downregulated. Alternatively, the chemokine-
receptor profile of the cell might change under the influence of other inflammatory cytokines or local 
conditions, such as hypoxia. This might help to retain the cell at the site of inflammation or to direct it 
elsewhere. 
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Table 4.2. Some of the chemokine receptors that are expressed on cancer cells. 
 
4.3 THE CXCR4/SDF-1 AXIS 
Stromal cell-derived factor 1 (SDF-1 or CXCL-12) is a chemokine originally isolated from 
a bone marrow stromal cell line (Doranz, 1999). SDF-1  is a 68-amino acid small (8 kDa) 
cytokine that belongs to the CXC chemokine family. SDF-1 is expressed in two isoforms, 
SDF-1α and SDF-1β, as two splice variants encoded by single gene mapped in 
chromosome 10. The two encoded proteins are almost identical, except for the last four 
amino acids of SDF-1β, which are absent in SDF-1α isoform. Biological and functional 
differences between the SDF-1α isoforms have not been described. It was long thought that 
CXCL12 bound exclusively to CXCR4 and that CXCR4 was its sole receptor, however 
recently CXCR7 was identified as another receptor for CXCL12 (Kryczek, 2007). 
SDF-1α binds to the receptors trough its RFFESH motif (amino acids 12 to 17). 
The gene CXCR4 maps on chromosome 2, at 2q21, and produces a  352-amino-acid 
protein; as the other chemokine receptor, CXCR4 is a 7-α-helix transmembrane 
metabolotropic receptors. 
Four cysteine residues situated on the extracellular side of CXCR4 generate two disulfide 
bonds pin respectively the base of the N-terminal segment to the tip of helix VII and the 
beginning to the end of the extracellular loop 2; these bonds are necessary to modulate 
ECL2 and the N-terminal segment (residues 27 to 34) shape to allow the binding of the 
ligand (Berson, 1996; Beili, 2010); The binding of SDF-1 to CXCR4 occurs on the N-
terminus of CXCR4 and the first extracellular loop. 
CXCR4 is expressed at high levels by various immune cells including monocytes, B cells, 
and naive T cells in peripheral blood (Aiuti, 1999). 
SDF-1, unlike most chemokines, is constitutively expressed in a broad range of tissues and 
therefore may have a role in immune surveillance rather than in inflammation (Bleul, 
1996). The most important sources of SDF-1 are bone marrow-, lymph node-, muscle- and 
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lung-derived fibroblasts (Zou, 1998), but it is also secreted by liver and kidney cells and in 
several regions of the central nervous system (Stumm, 2002). SDF-1 is involved in 
embryogenesis, for the colonization of bone marrow by fetal liver-derived hematopoietic 
stem cells, while later in adult life it plays an essential role in retention/homing of these 
cells into the marrow microenvironment. 
SDF-1-stimulated cell motility and chemotaxis occurs as a result of cytoskeletal 
rearrangements, actin polymerization, polarization, pseudopodia formation, focal adhesion 
and integrin-dependent adhesion to endothelial cells and other biologic substrates trough 
activation of different components, such as proline-rich kinase-2 (Pyk-2), p130Cas, focal 
adhesion kinase, paxilin, Crk and Crk-L, protein kinase C, phospholipase C-γ (PKC-γ ) as 
well as MAPK p42/44-ELK-1 and PI-3K-AKT-NF-κB axes (Ganju, 1998; Tilton, 2000; 
Helbig, 2003; Neuhaus, 2003; Majka, 2000, Libura, 2002). CXCR4 signaling also involves 
several src-related kinases and T-cell activating molecule ZAP-70 (Kremer, 2003).  
In some cells also STAT family members, such as JAK2, JAK3 (Ganju, 1998) and Tyk-2 
are associated with CXCR4 and are activated by trans-phosphorylation, in a Gαi-
independent manner (Vila-Coro, 1999) (fig. 4.3.1).  
SDF-1 is also able to induce adhesion of cells to fibrinogen, fibronectin, stroma and 
endothelial cells. This pro-adhesive effect of SDF-1 is mediated by the activation of various 
adhesion molecules, for example integrins, on the surface of target cells or increasing their 
de novo expression on the cell surface. SDF-1 is reported to activate integrins LFA-1 
(lymphocyte function associated antigen-1), VLA-4 (very late activation antigen-4) and 
VLA-5 (very late activation antigen-5) on immature human hematopoietic cells (Peled, 
2000).  
SDF-1 stimulates survival and proliferation of hematopoietic cells: it has been described as 
an autocrine survival factor for purified CD34+ CD38+ bone marrow mononuclear cells 
and this pro-survival effect was PI-3K-AKT axis dependent (Lataillade, 2002).  
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Figure 4.3.1. A schematic representation of the CXCR4/SDF1α intracellular signal transduction 
pathways (Teicher, 2010). 
 
The biological function of SDF-1/CXCR4 axis is modulated by several external factors. 
Hyposulfation of N-terminal tyrosine residues (Farzan, 1999) or enzymatic 
processing/cleavage of CXCR4 N-terminus by the leucocyte-derived proteases inhibits 
CXCR4 signaling (Valenzuela-Fernandez, 2002). Similarly, to CXCR4, also SDF-1 may 
also be cleaved by proteases released from activated leucocytes (Delgado, 2001) and in 
addition it may also be N-terminally truncated by cell surface expressed 
CD26/dipeptidylpeptidase IV (Christopherson, 2002).  
Several molecules may increase the sensitivity/responsiveness of CXCR4+ cells to SDF-1: 
for example C3a anaphylotoxin, platelet-derived microvesicles, hylauronic acid and several 
other molecules such as fibronectin, fibrinogen, thrombin, soluble UPAR and VCAM-1. So 
it is clear that the SDF-1/CXCR4 axis on haematopoietic cells may be modulated by several 
molecules related to inflammation (C3a anaphylatoxin, hyaluronic acid, upar, thrombin) or 
cell activation (membrane-derived vesicles).  
Molecules able to desensitize CXCR4 signaling are MIP-1α and RANTES in B- and T-
lymphocytes, activating another G-protein coupled chemokine receptor-CCR5 (Hecht, 
2005). SDF-1/CXCR4 axis may be also negatively modulated by heparin and 
lipopolysaccharides (Kucia, 2004) (fig. 4.3.2).  
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Figure 4.3.2. A schematic representation of the CXCR4-SDF- 1 pathway regulation (Kucia, 2004). 
 
In the BM, CXCL-12 is produced by stromal cells and it can be regulated by several 
factors. For example, oncostatin M, a regulator of HSCs homeostasis, retains HSCs in bone 
marrow through upregulation of CXCL-12 expression. Conversely, fibroblast growth factor 
2 (FGF-2) downregulate expression of CXCL-12 in BM stromal cells (Broxmeyer, 2008).  
 
4.3.1 The CXCR4/SDF-1 pathway in cancer 
Tumour cells from at least 23 different types of human cancers of epithelial, mesenchymal 
and haematopoietic origin express CXCR4 (Balkwill, 2004) and blockade of CXCR4–
CXCL12 interactions has been extensively investigated as a potential cancer therapeutic. 
Not all cancerous cells in the primary tumour are CXCR4 positive. In ovarian and non-
small-cell lung cancer, for instance, only a sub population of cells expresses this receptor 
(Scotton, 2001; Kijima, 2002).When it has been possible to study freshly isolated tumour 
cells the CXCR4 receptor is functional and various signaling pathways are activated. 
CXCL12 is the only known ligand for CXCR4. It is found in primary tumour sites in 
lymphoma and glioma, and ovarian and pancreatic cancer (Corcione, 2000; Zhou, 2002;  
Koshiba, 2000; Scotton, 2002) and at sites of metastasis in breast and thyroid cancer, 
neuroblastoma and haematological malignancies (Muller, 2001, Hwang, 2003; Geminder, 
2001). 
Increased expression of CXCR4, is associated with a poor prognosis and are associated 
with advanced and metastatic disease (Sun, 2003; Kato, 2003). The ability of tumour cells 
to use CXCR4–CXCL12 during the process of metastasis might depend on chemokine 
gradients in the primary tumour, as well as common sites of spread, levels of functional 
receptor, and the presence of other cytokines and proteases that can cleave ligand and 
receptor. 
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4.3.1.1 Role of CXCR4/SDF-1 pathway in MM  
Given its normal functions, it is easy to understand that the SDF-1/CXCR4 axis is involved 
in tumor progression. The BM microenvironment facilitates the survival, differentiation and 
proliferation of malignant cells through the secretion of factor such as IL-6 and SDF-1, 
while integrins-mediated adhesion sequesters tumor cells to this niche. Indeed, the SDF-
1/CXCR4 pathway is responsible for retention in the BM of acute lymphoid leukemia 
(ALL), acute myeloid leukemia (AML) and multiple myeloma (MM) cells (Juarez, 2007; 
Nervi, 2009; Azab, 2009). 
The SDF1α/CXCR4 axis is a key-regulator of MM cell homing, adhesion and motility 
(Katz, 2010). The CXCR4/SDF1α axis, regulates the mobilization and extravasation of 
tumor cells in bone (Alsayed, 2007). In MM, SDF-1 is expressed by stromal cells and led to 
a rapid activation of pERK1/2 and pAKT downstream of PI3K and this leads to cells 
migration; while CXCR4 is expressed by myeloma cells and endothelium, but not by 
marrow stromal cells (Baggiolini, 1998; Durig, 2001). Migration of myeloma cells across 
the endothelium lining the bone marrow sinuses is a critical step in the pathogenesis of 
multiple myeloma, which leads to homing and localization of these cells. As mentioned 
above, several studies have suggested that SDF-1 is a chemoattractant for human CD34+ 
hemopoietic progenitor cells. Similarly, in multiple myeloma, there is a positive correlation 
between SDF-1 protein levels and of chemotactic activity:  SDF-1/CXCR4 promotes 
transendothelial migration of myeloma cells by transient upregulation of VLA-4 
(α4β1)/VCAM-1, inducing cell adhesion to the endothelium, and contributing to the 
trafficking of myeloma cells in the bone marrow microenvironment (Parmo-Cabanas, 2004; 
Wright, 2003). 
Once myeloma cells are within the bone marrow, they localize in close proximity to stromal 
cells, forming tumor niche. In addition, SDF-1 secretion by marrow stromal cells is 
upregulated by adhesion of MM cells to stromal cells, thus promoting greater expression of 
integrins which enhance homing (Hideshima, 2002). 
CXCR4/SCDF-1 also plays a key role in chemotherapy-based mobilization of 
hematopoietic stem cells (HSC) and progenitor cells from BM to peripheral blood.  In vivo 
studies have shown decreased serum levels of SDF-1 in mobilized myeloma cells (Gazitt 
2004) potentially to confine the cells to the marrow and to prevent further trafficking of the 
cells (Alsayed, 2007). 
Interestingly, SDF-1 can also be protective against dexamethasone-induced apoptosis 
through activation of the mitogen-activated protein (MAP) Akt pathway, suggesting a role 
in drug resistance. SDF-1/ CXCR4 induces NF-κB activation in MM cells, which is 
consistent with previous reports of SDF-1α-induced NF-κB activation in primary osteocytes 
(Hideshima, 2002; Han, 2001). NF-κB has both growth-inducing and anti-apoptotic roles in 
normal cells as well as myeloma cells. SDF-1/CXCR4 also plays an indirect role in 
promoting growth, survival, and migration of MM cells by increased IL-6 and VEGF 
secretion in marrow stromal cells (Hideshima, 2002). 
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Finally, CXCL-12 expression in MM PCs can be induced by hypoxia. The BM 
microenvironment is physiologically hypoxic, a pre-requisite for normal bone marrow 
hematopoiesis. Hypoxia is an important selective force for the evolution of tumor cells and 
aberrant hypoxia-inducible transcription factor (HIF) is associated with highly aggressive 
phenotype. HIF-1α is widely expressed throughout the bone marrow, while HIF-2α is 
restricted to macrophages and CD138+ cells. This finding suggest that HIF-2 α is associated 
with malignant transformation of MM cells, since HIF-induced CXCL-12 stimulates in vivo 
angiogenesis (fig. 4.3.1.1) (Martin, 2010). 
 
 
Figure 4.3.1.1. Signalling cascades enhanced by CXCR4/SDF-1 mediating growth, survival and 
migration in multiple myeloma cells. The proliferation of multiple myeloma (MM) cells is mediated 
through the RAS/RAF/mitogen-activated protein kinase (MAPK) kinase (MEK)/MAPK pathway. 
Survival is mediated through Janus kinase (JAK)/signal transducer and activator of transcription 3 
(STAT3) and upregulation of BCL-XL and MCL1. Anti-apoptosis is also mediated by 
phosphatidylinositol 3-kinase (PI3K)/AKT signalling, with downstream activation of BAD and 
nuclear factor-κB (NF-κB), and/or inactivation of caspase-9. NF-κB and forkhead in 
rhabdomyosarcoma (FKHR) modulate cyclin D and KIP1, thereby regulating cell-cycle progression. 
Signalling through PI3K induces downstream protein kinase C (PKC) activity and MM cell 
migration. IGF1, insulin-like growth factor-1; IL, interleukin; SDF-1α, stromal-cell-derived factor-
1α; TNF-α, tumour-necrosis factor-α; VEGF, vascular endothelial growth factor. 
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MATERIALS AND METHODS 
 
 
1. CELL CULTURES 
 
1.1 Single cultures 
The Multiple Myeloma (MM) cell lines used were:  
KMS-12: cell line established from the bone marrow of a 64-year-old woman with a 
multiple myeloma. Cells negative for CD3, CD80, CD19  e CD20 and positive for CD138. 
They grow slightly adherent. 
RPMI-8226: cell line established from the peripheral blood of a 61-year-old man with 
multiple myeloma (IgG lambda-type) at diagnosis in 1966; described to produce and 
secrete only lambda light chains (but not heavy chains). Cells negative for CD19  and 
CD20 and positive for CD28 , CD138 and CD49. They grow slightly adherent. 
OPM-2: cell line established from the peripheral blood of a 56-year-old woman with 
multiple myeloma (IgG lambda) in leukemic phase (relapse, terminal) in 1982. Cells 
negative for CD3 , CD10, CD80, CD19  and CD20 and positive for CD138. They grow in 
suspension.  
All MM cell lines were maintained in 75 cm2 flask in RPMI 1640 medium (Sigma-Aldrich 
Co., St Louis, MO), supplemented with 10% (v/v) FBS (Gibco, Rockville, MD), 2 mM L-
glutamine (Invitrogen Corporation Carlsbad, CA, USA), 100 U/ml penicillin and 100 µg/ml 
streptomycin. The serum was de-complemented for 30’ at 56°C before use. Cells were 
cultured in 5% CO2 at 37°C, maintaining the optimum concentration at 3x105cells/ml with 
complete change of medium every two days. 
 
The Bone marrow stromal cell (BMSC) line used was:  
NIH-3T3: cell line of mouse embryonic fibroblasts isolated in 1962 at the New York 
University School of Medicine Department of Pathology. 3T3 refers to the sub-cultivation 
protocol and it means "3-day transfer, inoculum 3 x 10^5 cells" (Todaro G.J., 1963). They 
grow adherent. Cell line was maintained in 10 cm2 plate dishes , in DMEM medium 
(Sigma-Aldrich Co., St Louis, MO, USA), supplemented with 10% (v/v) FBS (Gibco, 
Rockville, MD, USA), 2 mM L-glutamine (Invitrogen Corporation Carlsbad, CA, USA), 
100 U/ml penicillin and 100 µg/ml streptomycin. The serum was de-complemented for 30’ 
at 56°C before use. Cells were cultured in 5% CO2 at 37°C. Cells have a doubling time of 
18-20h and were divided three times/ week. 
 
1.2 Co-culture of MM/BMSC lines 
NIH-3T3 cells were plated in 24 multi-well plates at the concentration of 150000/ml. After 
24h NIH-3T3 medium was discarded and OPM-2 MM cells were plated on top of NIH-3T3 
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monolayer at the concentration of 350000/ml. All the co-cultures were maintained in RPMI 
1640 medium (Sigma-Aldrich Co., St Louis, MO), supplemented with 10% (v/v) FBS 
(Gibco, Rockville, MD), 2 mM L-glutamine (Invitrogen Corporation Carlsbad, CA, USA), 
100 U/ml penicillin and 100 µg/ml streptomycin. The serum was de-complemented for 30’ 
at 56°C before use. Cells were cultured in 5% CO2 at 37°C for 48h. 
 
 
2. CELLS COUNT 
Viable cells were counted by die-exclusion method: an equal volume of cells and Trypan 
Blue solution (Sigma-Aldrich Co.) was mixed; only viable cells were counted in the 
Burker-type chamber (figure 2.1) with an optical microscope.  
 
Figure 2.1. Burker-type chamber 
 
The following formula was used to calculate the cellular concentration: 
 
 
3. TREATMENTS 
 
3.1 Notch inhibition GSI-XII-mediated 
GSI XII (γ-secretase inhibitor XII - (N2-[(benzyloxy)carbonyl]-N1-[(2S)-4-methyl-1-
oxopentan-2-yl]isoleucinamide) (Calbiochem, figure 3.1), a γ-Secretase inhibitor, was 
dissolved in DMSO at the concentration of 12 mM. Notch inhibition was obtained culturing 
3* 105 cells/ml in the presence of 6 µM GSI-XII for 48h. The controls were treated with 1% 
DMSO (GSI vehicle). 
 
Figure 3.1. Chemical structure of  GSI-XII 
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3.2 CXCR4 inhibition AMD3100-mediated 
AMD3100 (fig. 3.2) (1,1′-[1,4-Phenylenebis (methylene)] bis-1,4,8,11-tetra-aza-cyclo-
tetradecane octa-hydrochloride, Sigma-Aldrich Co.) is a highly specific chemokine receptor 
CXCR4 antagonist. 
7x105 cells/ml were treated or not with AMD3100 (1-5-10-15 µM) for 48h in 96 well-
plates. 
 
 
Figure 3.2. AMD3100 structure 
 
3.3 SDF-1 inhibition trough neutralizing antibody 
7x105 cells/ml were treated with 100µg/ml of neutralizing mouse antibody IgG1 anti-human 
SDF-1 (R&D) (fig. 3.3) and matched isotypic control for 48h in 96 well-plates. 
 
 
Figure 3.3. Mechanism of action of neutralizing Ab anti-SDF-1  
 
 
3.4 Exogen SDF-1 treatment 
Recombinant human SDF-1 (Peprotech, NJ, USA) was given at 0.5 µg/mL (for reversal of 
GSI XII-dependent inhibition) or at 75 ng/ml (for chemotaxis assay) to 3x105 cells/ml. 
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4. GENE EXPRESSION ANALYSIS 
 
4.1 RNA isolation 
The total RNA isolation was based on acid guanidinium thiocyanate-phenol-chloroform 
extraction (Chomczynski P., 1987).The protocol is optimized for 106 cells: 
• Cells were washed two times with cold 1X PBS.  
• After centrifugation at room temperature, pellet was resuspended in 150 µl of D-
solution. 
• Sequentially it was added: 
- 15 µl Sodium Acetate 2M pH 4 
- 150 µl water-saturated Phenol 
- 30 µl Chloroform-Isoamyl alcohol (98% Chloroforme, 2% Isoamyl Alcohol) 
• Sample was mixed by vortex and incubated at 4°C for 10’. 
• After centrifugation for 10’ at 14.000 rpm at 4°C, the aqueous phase was collected in 
a new tube. 
• One volume of Phenol-Chloroform was added to the aqueous phase. 
• Sample was mixed by vortex and centrifuged for 10’ at 14.000 rpm at 4°C. 
• The aqueous phase was collected in a new tube.  
• One volume of cold isopropanol was added to the aqueous phase. 
• Sample was incubated for 30’ at –20°C. 
• After centrifugation for 30’ at 14.000 rpm at 4°C, the supernatant was discarded. 
• Pellet was resuspended in 50 µl of D-Solution and precipitated with 1 volume of cold 
isopropanol.  
• Sample was incubated for 30’ at –20°C. 
• After centrifugation for 30’ at 14.000 rpm at 4°C, the supernatant was discarded. 
• Pellet was washed with cold ethanol 70% . 
• After centrifugation for 10’ at 14.000 rpm at 4°C, the ethanol was discarded. 
• Pellet was dried with vacuum system and resuspended in 30 µl of H2O DEPC. 
• To obtain an homogenous solution, RNA was heated at 65°C for 5’. 
 
PBS 1X pH 7,4 
- 4,3 mM  Na2HPO4 
- 1,47 mM  KH2PO4 
- 137 mM  NaCl 
- 2,7mM  KCl 
 
D-Solution pH 7: 
- 4 M  guanidinium isothiocyanate 
- 25 mM sodium citrate tribasic dehydrate 
- 18.4 mM sodium lauroyl sarcosinate 
- 100 mM β-mercaptoethanol 
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4.2 RNA quantification 
RNA was quantified by spectrophotometric measure, using 2 µl of RNA in 700 µl of H2O 
Milli-Q in quartz cuvettes at two different wavelengths: 260nm (A1) and 280nm (A2). 
Since: 1 OD260nm = 40 µg/ml 
 
The concentration in µg/ml was calculated as: 
A260 x 40 ng/µl x dilution factor 
High quality RNA was used (A1/A2 ratio closed to 2). 
 
 
4.3 Reverse transcription 
The cDNA was obtained by reverse transcription with M-MLV RT KIT (Sigma-Aldrich 
Co.).  
• A reaction mix of 20 µl was prepared with: 
- 2 µl of Random primers (250ng/µl)  
- 4 µl of 10 mM dNTPs (2.5mM each)  
- 2 µg RNA 
- H2O DEPC up to 10 µl 
• The sample was heated at 65°C for 5’. 
• After centrifugation it was added to the mix:  
- 2µl of 10x M-MLV RT Buffer  
- 1µl of M-MLV Reverse Transcriptase (200 U/µl) 
- 7µl of H2O DEPC 
• Sample was incubated 10’ at room temperature, then at 37°C for 50 minutes and 
finally stored at –20°C. 
 
4.4 PCR (Polymerase Chain Reaction)  
The cDNA obtained by reverse transcription was used as template for PCR reaction. 
A final reaction volume of 20 µl was prepared with: 
- 4 µl 5X Buffer Green (Promega) 
- 1.6 µl Mg 2+  25mM 
- 1.6 µl of 2.5mM dNTPs  
- 4 µl Primer mix (5 µM each) 
- 0.1 µl Taq Polimerase (5U/µl, Promega) 
- 2 µg cDNA 
- H2O MilliQ to 20 µl 
cDNA levels were evalueted by densitometric analysis through agarose gel electrophoresis, 
and normalized with GAPDH. 
 
Primer sequences used for cDNA amplification are displayed in Table 4.4.1: 
58 
 
 
Table 4.4.1 
 
The used amplification program was the following: 
 
 
The used amplification conditions are displayed in Table 4.4.2: 
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Table 4.4.2 
 
4.5 Electrophoresis 
Agarose gel was prepared dissolving the agarose powder (Sigma-Aldrich Co.) in 1X TBE at 
100°C. 2µl of 10µg/ml ethidium bromide solution (Sigma-Aldrich Co.) was added to 100 
ml of agarose solution. The ethidium bromide intercalates in the double strand nucleic acids 
and emits fluorescence when illuminated with ultraviolet light. The DNA samples were 
loaded with 6x loading dye (Fermentas).  
 
TBE 1X 
- 890 mM Tris base (Sigma-Aldrich Co.)           
- 890 mM boric ACID (Sigma-Aldrich Co.) 
- 20 mM  EDTA (Sigma-Aldrich Co.) 
- H2O 
 
4.6 Quantitative PCR  
Quantitative PCR reactions were carried out on a 7500 Fast Real-time PCR system 
(Applied Biosystems, Life Technologies Italia, Italy) using the GoTaq qPCR Master Mix 
(Promega, Italia s.r.l., Milan, Italy). 
Each sample was analyzed in triplicate with no template controls. Calculations of the initial 
mRNA copy numbers in each sample were made according with to Ct (cycle-mix 
threshold) method and the copy numbers of the analyzed mRNA were normalized using 
GAPDH mRNA levels. Primer sequences used for cDNA amplification are displayed in 
Table 4.6 and Table 4.7: 
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Table 4.6. 
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Table 4.7. 
 
5. FLOW CYTOMETRY ANALYSIS 
To evaluate the apoptosis status, cell cycle distribution, protein expression a Beckman 
Coulter  flow cytofluorimeter was used. Cells were processed using “Cytomics FC500” 
Beckman Coulter software program. Mean log fluorescence intensity (MFI) values were 
obtained by subtracting the MFI of the isotype control  (or unstained sample) from MFI of 
the positively stained sample. 
 
5.1 Detection of apoptosis 
3x105 cells/ml were washed with cold PBS1x, resuspended in “binding buffer 1X” (HEPES 
0,01M, NaCl 0,14M, CaCl2 2,5mM) and incubated (or not for control) for 15’ at room 
temperature with Annexin-V FITC (Bender) + Propidium Iodide (2,5 ug/ml final, Sigma-
Aldrich Co) in the dark. Finally, 400 µl of Binding Buffer 1x were added to the tube. 
10.000 cells with Beckman Coulter analyzer were acquired using FL1 and FL3 bandpass 
filter for Annexin-V FITC (λex=488 nm; λem=520 nm) and Propidium Iodide (λex=488 
nm; λem=617 nm) respectively. Cells were processed using “Cytomics FC500” 
BeckmanCoulter software program.  
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5.2 Cell cycle assay 
3x105 cells/ml were washed with cold PBS and resuspended in “GM Buffer” 1x (PBS, 
glucose 1mg/ml, EDTA 0,2 mg/ml,  2% FBS). Cells were fixed on vortex with Ethanol 
(70% final), incubated for 10’ at 4°C and washed in PBS/5% FBS. Cells were incubated in 
PBS/ Rnase 25µg/ml / Propidium Iodide 25µg/ml / NP-40 0,004% for 1h at 37°C. 10000 
cells were acquired with Beckman Coulter analyzer using FL2 bandpass filter for 
Propidium Iodide (λex=488 nm; λem=617 nm). Cells were processed using “Cytomics 
FC500” BeckmanCoulter software program.  
 
5.3 CXCR4 cell surface staining 
For extracellular staining of CXCR4, 3x105 cells/ml were harvested and resuspended in 
blocking solution (PBS, 1%FBS) for 10 minutes at room temperature, centrifuged and 
incubated for 30 minutes at 4°C in the dark with Mouse IgG2A anti-Human CXCR4 APC 
Mab or Mouse IgG2A APC Isotype Control (BD) (both 1:5) in PBS/ 2% FBS/ 0,1% NaN3. 
10000 cells were acquired with Beckman Coulter analyzer using FL4 (red laser) bandpass 
filter (λex=633nm; λem=660nm) for APC fluorofore conjugated Ab. 
Cells were processed using “Cytomics FC500” BeckmanCoulter software program. The 
analysis was determined by overlaying the histogram of the samples stained with specific 
Ab and isotype control. The percentage of CXCR4 expressing cells was obtained by 
subtracting the  isotype control percentage  from that of the positively stained sample. 
 
5.4 SDF-1 intracellular staining 
For intracellular staining of SDF-1, 3x105 cells were harvested and resuspended in 0.1mL 
PBS containing 1% BSA and 0.1% NaN3. Then, cells were fixed by adding 1 volume of 4% 
formaldehyde in PBS, mixing thoroughly and incubating for 20 minutes at room 
temperature. After centrifuging at 1,500xg for 5 minutes, cells were resuspended in 0.1 mL 
permeabilization buffer (0.5% saponin + 0.5% BSA in PBS) and allowed to incubate for 10 
minutes at room temperature. Then cells were centrifuged, resuspended in 20 µL 
permeabilization buffer and 2 µL of APC-conjugated mouse anti-human SDF-1 or isotype 
matched control were added (R&D Systems, Inc., MN, USA). After 1 hour incubation at 
4°C in the dark, cells were washed once with 0.3 mL permeabilization buffer, then twice 
with 0.3 mL PBS before acquisition.  
10000 cells were acquired with Beckman Coulter analyzer using FL4 (red laser) bandpass 
filter (λex=633nm; λem=660nm) for APC fluorofore conjugated Ab. 
Cells were processed using “Cytomics FC500” BeckmanCoulter software program. The 
analysis was determined by overlaying the histogram of the samples stained with specific 
Ab and isotype control. The percentage of SDF-1 expressing cells was obtained by 
subtracting the  isotype control percentage  from that of the positively stained sample. 
 
5.5 ICN intracellular staining 
For the detection of active Notch1 (intracellular Notch-ICN), cells were washed in PBS, 
fixed with methanol, permeabilized with PBS supplemented with 0.5% (W/V) BSA and 
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0.5% (V/V) Tween-20 (permeabilization buffer), then resuspended in PBS + 10% FBS. 
Cells were labeled at room temperature using rabbit anti-Val1744 antibody (Cell Signaling 
Technology, Inc., MA, USA; 1:15 final dilution) for 30 minutes in permeabilization buffer. 
After washing in PBS, the PE-conjugated anti-rabbit antibody was added (Santa Cruz 
Biotechnology, Inc., CA, USA). 10000 cells were acquired with Beckman Coulter analyzer 
using FL2 bandpass filter (λex=488nm; λem=575nm) for R-PE fluorophore conjugated Ab. 
Cells were processed using “Cytomics FC500” BeckmanCoulter software program. The 
analysis was determined by overlaying the histogram of the samples stained with specific 
Ab and isotype control. The percentage of ICN expressing cells was obtained by 
subtracting the  isotype control percentage  from that of the positively stained sample. 
 
5.6 PKH plasma membrane staining 
PKH26 (Sigma Aldrich, Co) vital dye is a reporter lipid-like molecules with fluorescent 
"head groups" and long aliphatic "tails". PKH molecules diffuse into the plasma  membrane 
of viable cells, leaving the fluorogenic moiety exposed near the outer surface of the cell. 
Labeled cells retain both biological and proliferative activity (fig. 5.6). 
3x105 cells/ml were washed with cold PBS1x, resuspended in 1ml of “Diluent C” (Sigma 
Aldrich, Co) and incubated (or not for control) for 5’ at room temperature with 1µl PKH 
dye solution. After two times whash PBS1x, cells were plated in normal culture medium or 
resuspended in PBS1x and acquired to flow cytometer. 
10.000 cells with Beckman Coulter analyzer were acquired using FL2 bandpass filter for 
PKH dye (λex=488nm; λem=575nm). 
 
 
 
 
Figure 5.6. Staining mechanism of PKH dye. 
 
6. ELISA ASSAY 
Measurement of SDF-1α concentration in conditioned medium from cultured MM cell lines 
was tested by ELISA assay. Supernatant of cells was collected in 96-well plates and coated 
1:1 with “coating buffer” (5.3g of Na2CO3 / 4.2g of NaHCO3/ 1g sodium azide ). After 
overnight incubation at 4°C, the plates were blocked with 1%BSA in PBS for 2 hours at 
room temperature. Incubation with primary antibody (Abcam, anti-human SDF-1α 1:500 in 
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PBS) occurred for 2 hours at 37°C. Plates were incubated with HRP-linked secondary 
antibody (Abcam, 1:4000 in PBS) for 2h at RT in the dark. Peroxidase substrate solution 
(KPL) was added and incubated for 5’ at RT in the dark. An automated microplate reader 
was used to measure the optical density at a wavelength of 450 nm. After each step, plates 
were washed four times with PBS containing 0.05% Tween 20. 
 
7. MTT ASSAY 
Cells were incubated with 0,5mg/ml MTT suspension (Sigma-Aldrich Co) in the dark at 
37°C 5%CO2 for 4h and finally resuspended in DMSO. An automated microplate reader 
was used to measure the optical density at a wavelength of 540nm (background 
wavelength= 620nm). Plates were processed using “Magellan” Tecan software program.  
 
8. CHEMOTAXIS ASSAY 
Cell migration induced by a chemotactic stimulus was analyzed using a polycarbonate filter 
(Transwell support, Corning Costar) that was interposed between a top compartment in 
which cells were placed and a bottom compartment that contained the chemokine. The filter 
had pore diameter defined that prevented the free passage of cells in the bottom 
compartment, but allowed their transition to active chemotaxis. Pores diameter used for 
MM cells were 8 µm. 
 
Protocol for chemotaxis assay: 
200.000/well cells were incubated in 600 µl of chemotaxis buffer (RPMI 1640, 1% BSA, 
25mM HEPES; pH 7,3-7,4) for 1 hour at 37 ° C and 5% CO2. 
• The chemokine was diluted in 600µl of chemotaxis buffer at 100 ng/ml and added in 
the lower chamber. 
• A cell suspension was prepared at a concentration of 2.000.000 cells/ml. 
• 100 µl of cell suspension were loaded (200,000 cells total) in the upper chamber. 
• Transwell were incubated for 4 hours at 37°C and 5% CO2. 
• The Transwell supports were discarded gently in order to recover in a tube all the 
medium from the lower chamber. 
• After a 3’centrifugation at 3000 rpm the supernatant was discarded. 
• Cells were resuspended in 100µl of PBS. 
• Burker-type chamber was used to count cells in duplicate. 
• The total number of migrated cells to the lower chamber was obtained from the cell 
concentration and the volume of resuspension. 
 
Each test point in the chemotaxis assay was performed in triplicate in each experiment to 
identify any possible value affected by technical errors diverging from the mean value. 
Cell migration was calculated as a Migration Index (MI) which represents the ratio between 
the number of cells migrated in response to the chemokine (specific migration to a gradient 
or chemotaxis) and the number of cells migrated in the absence of chemokine (nonspecific 
migration). The M.I. is a measure of net migration to the chemokine gradient: if the value is 
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equal to one, the chemotactic stimulus is completely ineffective; if it is higher than 1, the 
chemokine induces a specific migration; if it’s lower than 1, the chemokine induces a 
repulsive effect. 
 
9. REVERSAL OF GSI XII-DEPENDENT NOTCH INHIBITION BY CHEMOKINE 
SDF-1α. 
3x105 cells/ml were double-treated with 2 µM GSI-XII and 500ng/ml SDF-1α together and 
each separately for 48h.  
 
10. TRANSFECTIONS AND PLASMIDS 
Extracellular domain-deleted Notch1 (∆E-N1) construct was as previously described 
(Kopan R. et al., 1994); pcDNA3.1  was from Invitrogen (Invitrogen Life Technologies 
Italia, Italy). 6 µg total DNA were used for electroporation. Exponentially growing cells 
were harvested and resuspended in BTXpress™ electroporation buffer (BTX, MA, USA). 
100ul of this suspension were mixed with 6 µg DNA, then transferred into a 2.0 mm-gap 
cuvette (BTX). Electroporation was performed using 150 V and 950 µF. Immediately after 
the electric pulse, cells were diluted in 2 ml complete medium. 24 hours later, cells were 
counted, harvested, and resuspended to 0.3x106 cells/ml. After 48h CXCR4 expression was 
detected by FACS analysis.  
 
11. RNA INTERFERENCE 
To selectively inhibit Notch signalling in MM OPM-2 cell line a specific Jagged1 and 2 
knock-down was designed using a transient expression of specific siRNAs for Jagged1-2. 
OPM-2 cells express high levels of Jagged1 and 2. Notch ligand up-regulation has been 
shown to enhance Notch activation in surrounding MM cells and BM stromal cells. As 
negative control was used a “scrambled” siRNA, to discount any change in gene expression 
profile due to delivery method. Cells treated with fluorescent sdRNA “BLOCK-IT” (Life 
Technologies Italia, Milan, Italy) were used as positive control. 
To address this issue, Stealth Select RNAiTM siRNA system (Life Technologies Italia, 
Milan, Italy) was used according to the Manufacturer’s guidelines. 
Specific anti-Jagged siRNAs were delivered following these steps: 
• Cells were plated at 3x105/ml in medium without antibiotics; 
• 24h later, cells were diluted to 3,6x105/ml in medium without antibiotics and plated in 
0,5 ml of final volume; 
• siRNAs (25 nM anti-Jagged1 + 25 nM anti-Jagged2 / or 50nM scrambled siRNA/ or 
50nM fluorescent dsRNA ) were diluted in 50µl of Opti-MEM medium (Invitrogen, 
Life Technologies Italia, Milan, Italy) without serum and antibiotics; 
• 1µl of RNAi-MAX lipofectamine transfecting reagent (Invitrogen, Life Technologies 
Italia, Milan, Italy) was diluted in 50µl of Opti-MEM medium  without serum and 
antibiotics; 
• The two solutions (siRNA/lipofectamine) were mixed and incubated for 20’ at room 
temperature; 
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• 100µl of lipofectamine/siRNA mix was added to the cells (final cells concentration 
3x105/ml); 
• Every 48h cells were diluted 1:1 with medium antibiotics-free and treated again with 
JAG1-2 siRNA up to 8 days 
 
Cells were maintained in RPMI 1640 medium (Sigma-Aldrich Co., St Louis, MO) 
supplemented with 10% (v/v) FBS (Gibco, Rockville, MD) and 2 mM L-glutamine 
(Invitrogen Corporation Carlsbad, CA, USA) without antibiotics and incubated in 5% CO2 
at 37°C. 
To confirm that the transfection occurred successfully, the percentage of BLOCK-IT 
positive cells were checked trough flow cytometry analysis at each time point. 10000 cells 
were acquired with Beckman Coulter analyzer using FL2 bandpass filter (λex=488nm; 
λem=575nm) for BLOCK-IT fluorophore conjugated sdRNA. 
Jagged1 and 2 effective silencing induced by specific siRNAs was assessed by quantitative 
PCR compared to scrambled siRNA-receiving cells. 
 
12. JAGGED1-2 KNOCK-DOWN AND DETECTION OF APOPTOSIS IN CO-
CULTURED CELLS. 
 
• OPM-2 cells were seeded at 300.000 cells/ml in medium without antibiotics and after 
24h the JAG1-2 siRNA treatment was added following the protocol previously 
described. 
• After 24h NIH-3T3 cells were labeled (or not for negative control) with PKH vital dye 
(Sigma-Aldrich, Co) and plated in 24 multi-well plates at the concentration of 
150.000/ml 
• 24h later, OPM-2 cells were diluted and treated once again with silencing treatment 
• After 8h NIH-3T3 medium was discarded while OPM-2 cells were washed with 
PBS1x and plated on the monolayer of NIH-3T3 cells at final 1:1 ratio.  
 
Co-cultures were manteined for 48h, obtaining in this way a condition in which MM cells 
were silenced from 4 days. 
Cells treated with scrambled siRNA were used as negative control. 
All the cultures for this experiment were maintained in RPMI 1640 medium (Sigma-
Aldrich Co., St Louis, MO) supplemented with 10% (v/v) FBS (Gibco, Rockville, MD) and 
2 mM L-glutamine (Invitrogen Corporation Carlsbad, CA, USA) without antibiotics and 
incubated in 5% CO2 at 37°C. 
 
48h co-cultured cell lines were collected and tested for the detection of apoptosis using the 
following method: cells were washed with cold PBS, re-suspended in “binding buffer 1X” 
(HEPES 0,01M, NaCl 0,14M, CaCl2 2,5mM) and incubated (or not for control) for 15’ at 
room temperature with Annexin-V FITC (Bender) in the dark. Finally, 400 µl of Binding 
Buffer 1x were added to the tube. 
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10.000 cells with Beckman Coulter analyzer were acquired using FL1 and FL2 bandpass 
filter for Annexin-V FITC (λex=488 nm; λem=520 nm) and PKH fluorescent dye 
(λex=488nm; λem=575nm) respectively. Cells were processed using “Cytomics FC500” 
BeckmanCoulter software program. 
Mean log fluorescence intensity (MFI) values were obtained by subtracting the MFI of the 
unstained sample from MFI of the positively stained sample. 
Using this staining method it was obtained a mixed population in which is possible to 
distinguish four regions (fig. 12.1): 
1. PKH+/Ann- population indicating NIH-3T3 living cells  
2. PKH+/Ann+ population indicating NIH-3T3 apoptotic cells 
3. PKH-/Ann- population indicating OPM-2 living cells 
4. PKH-/Ann+ population indicating OPM-2 apoptotic cells 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 12.1. Schematic representation of four Dot-Plot regions resulted from PKH/Annexin 
cellular staining. 
 
13. STATISTICAL ANALYSIS  
All experiments were performed in triplicate and repeated 3 times. 
Statistical analysis has been performed by t-test and ANOVA test. Significative differences 
have been reported: * = p<0,05; ** = p<0,01. Non-significative differences have been 
reported: # = p> 0,05. 
 
FL1 Annexin FITC 
FL2
PKH 1 2 
3 4 
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AIMS 
 
 
Multiple myeloma (MM) is a malignant plasma cell disorder that accounts for 
approximately 10% of all hematologic cancers and is characterized by skeletal destruction, 
renal failure, anemia, and hypercalcemia. Although the recent advances in its treatment, 
myeloma remains incurable, with a median survival of 3-4 years after diagnosis. 
The Notch signaling pathway is a highly conserved developmental pathway, which plays a 
critical role in cell-fate decision, tissue patterning and morphogenesis. Its deregulation is 
often associated to cancer onset and progression. In particular, MM is frequently 
characterized by iperexpression of the Notch ligand, Jagged2. Moreover Notch receptors 
(Notch 1, 2 and 3) are expressed on primary MM cells, while Notch ligands (Jagged-1 and 
Jagged-2) are expressed on MM and BMSC and are able to activate Notch signaling 
through homotypic as well as heterotypic interactions in MM cells, influencing tumor 
growth and survival and the interaction with the surrounding microenvironment. Indeed, 
there are evidences that the inhibition of NOTCH signaling in MM cells may induce 
apoptosis of MM cells and may also enhance the effect of chemotherapy. 
This thesis work aims to provide experimental evidences about the effect of Notch pathway 
deregulation in the context of MM. 
Several approaches were used to study how the NOTCH pathway could influence the MM 
cell growth and the signaling of chemokines and chemokine receptors involved in 
pathogenesis and development of MM.  
Particular attention was given to the CXCR4/SDF1α pathway because of its relevance in 
MM since recent evidenced showed its role in the mobilization and intravasation of primary 
malignant plasma cells resulting in multiple bone metastasis. 
Accumulating evidences shows that the cellular interplay between MM and bone marrow 
(BM) microenvironment mediates MM growth, acquired drug resistance and the formation 
of bone-destructive lesions.  
BM microenvironment consists of soluble factors such as cytokines, chemokines and 
growth factors, as well as cellular components, e.g. stromal cells, osteoblasts, osteoclasts, 
vascular elements and immune cells. The interplay among these elements and malignant 
plasma cells generates a cellular loop suitable for MM growth, survival and protection from 
drugs, that is generally referred to as the ‘‘MM niche’’.  
To better understand role of Notch signalling in MM progression and the pathological 
relationship with the BM tumoral microenvironment, I studied the effect of Notch 
modulation on MM cell lines and further reproduced “in vitro” the tumoral 
microenvironment conditions through co-culture experiments. 
The final goal of this investigation is to obtain further evidences concerning the clinical 
relevance of NOTCH signaling as a therapeutic target in MM. 
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RESULTS 
 
 
1. NOTCH BLOCKADE INHIBITS MM CELL LINES 
PROLIFERATION AND VIABILITY BY AFFECTING CELL 
CYCLE PROGRESSION AND APOPTOSIS. 
 
The inhibition of the NOTCH pathway was obtained by using a γ-secretase inhibitor: GSI-
XII. This compound, binds reversibly to the γ-secretase enzymatic complex, blocking the 
cleavage of NOTCH intracellular domain and thus preventing the release of the protein 
fragment from the membrane and its translocation to the nucleus and therefore its 
transcriptional function. Gamma-secretase inhibitors carry out their action 
contemporaneously on all the NOTCH isoforms present on cell membrane (fig. 1.1). 
 
 
Figure 1.1. Mechanism of action of the drug GSI XII 
 
To evaluate the effect of Notch inhibition on MM, our model cell lines, OPM-2, KMS-12 
and RPMI-8226 (see Materials and Methods for details),were seeded at 300.000 cells/ml 
and treated with 6 µM GSI-XII or an equal amount of the vehicle (DMSO, 0.015% V/V) 
for 48h. The analysis of cell proliferation was made through the count with Burker-type 
chamber of viable cells excluding Trypan Blue vital dye. 
Notch pathway inhibition trough GSI-XII had a negative effect on cell growth and reduced 
the number of viable cells compared with DMSO (fig. 1.2). 
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Figure 1.2. Evaluation of the biological effects of GSI XII on MM cell lines proliferation at  48 h. 
Mean values of cell counts from three independent experiments ± SD are reported;s tatistical analysis 
was performed using one-tailed t-test. (*= P <0.05, **= P <0.01; ***= P <0.001.) 
 
According to these results, Notch is involved in changes in MM cell number, therefore it 
was interesting to identify  the causes of this effect. 
To address this issue, cell cycle variations occurring on MM cell lines treated in the same 
conditions of the previous experiment were observed. Cells were collected, permeabilized 
and stained with Propidium Iodide (PI, a DNA intercalating dye which allows to measure 
DNA content, whose amount is dependent by the phase of the cycle that cells are flowing 
through [G1/G0 =.2N; G2/M=4N]) and analyzed by flow cytometry. 
Cell cycle distribution analysis (fig. 1.3) revealed that GSI-XII significantly increased the 
G2/M phase; G2/M phase increment matched with a comparable reduction in both G0/G1 
and S phases in all cell lines tested. 
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Figure 1.3. Cell cycle analysis of MM cell lines with and without GSI-XII. DNA content was 
measured after 48h of  GSI-XII treatment, The values indicate the percentage of cells in each phase of 
cell cycle and are representative of three independent experiments. 
 
This result indicates that the reduced cell growth occurring after GSI-XII treatment is, at 
least in part, due to G2/M phase cell cycle arrest. 
GSI-XII-triggered cell growth inhibition effect on MM cell lines apoptosis rate was 
investigated. Apoptosis assay was performed on MM cell lines treated or not with GSI-XII  
trough the Annexin-IV/PI double staining method and analyzing positive cells by flow-
cytometry (see Material and Methods). GSI-XII treatment resulted in ~ 40-50% increased 
frequency of Annexin-V+ cells compared with controls (fig. 1.4). 
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Figure 1.4. Apoptosis assay of MM cell lines treated (or not) with GSI-XII for 24h and 48h. Dot-
plots deriving by flow cytometric analysis are reported. Values represent the percentage of cells in 
early (Ann+/PI-) or late (Ann+/PI+)apoptosis and are representative of three independent 
experiments. 
 
2. NOTCH  REGULATES SEVERAL CHEMOKINE RECEPTORS 
AND THEIR LIGANDS IN MM CELL LINES 
 
Several chemokine receptors are overexpressed in MM and are involved in osteolysis 
occurring at tumor BM localization sites. This consideration prompted us to investigate the 
effect of NOTCH on the expression of chemokine receptors and their ligands. 
The same MM cell lines were plated at the concentration of 300,000 cells/ml and treated 
with GSI XII 6µM or the vehicle for 48h. The effect of NOTCH inhibition on chemokine 
receptors and their ligands was analyzed through RT-PCR: this first screening was 
performed on CXCR4, CCR1, CCR5 and their ligands, which were chosen on the basis of 
their relevance in MM system, as reported in Introduction. The expression level of Hes1 
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gene (Notch direct target gene) was evaluated as indicative of Notch activation, and 
therefore of the efficacy of GSI-XII inhibiting treatment. 
The GSI-XII treatment of the three cell lines (compared to control cells) caused a reduction 
of the HES1 gene mRNA level indicating that the Notch pathway was effectively inhibited. 
A parallel decrease of the three chemokine receptors CXCR4, CCR1, CCR5 and of SDF-1 
gene (CXCR4 ligand) was observed, while all the CCR1/CCR5 ligands examined, 
displayed an increase in the mRNA levels (fig. 2.1). 
 
 
Figure 2.1. Expression of chemokine and their receptor genes in MM cell lines treated with GSI 
XII for 48 h. Treatment with GSI XII reduces CXCR4 and its ligand SDF-1 and CCR5 and CCR1 
expression, but increases the levels of their ligands in all the MM cell lines. Gene expression is 
normalized on the expression level of the housekeeping gene GAPDH. The above images are 
representative of three independent experiments. 
 
 
According to these results the CXCR4/SDF-1 pathway is negatively regulated by Notch 
inhibition; this evidence prompted me to futher investigate the role of this pathway as 
downstream effector of Notch in MM. 
 
3. NOTCH INHIBITION DOWN-REGULATES CXCR4 AND ITS 
LIGAND SDF-1 AT mRNA AND PROTEIN LEVELS. 
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The effects of NOTCH inhibition on chemokine receptor CXCR4 and its ligand SDF-1 
were analyzed in MM cell lines. 
The same MM cells were plated at the concentration of 300,000 cells/ml and treated with 
GSI XII 6µM or the vehicle for 48h. 
A quantitative PCR analysis was performed to precisely evaluate variations in HES-1, 
CXCR4 and SDF-1 levels following GSI-XII treatment. Transcript fold change was 
calculated (as reported in material and method) to compare GSI-XII-treated with control 
cells. GSI-XII significantly reduced the levels of HES-1 mRNA in all the tested cell lines, 
indicating that the Notch pathway was effectively inhibited. This inhibition was associated 
with a significative CXCR4 and SDF-1 down-regulation (fig. 3.1).  
 
 
Figure 3.1. Real time PCR analysis of GSI-XII effect on CXCR4 and SDF-1α gene expression. 
Histograms represent the mean values +/-SD calculated on three independent experiments run in 
triplicate. GAPDH was used as internal reference. 
 
 
To further investigate whether the GSI-XII-mediated inhibition of CXCR4 mRNA 
expression affected the amount of the receptor on cell surface, a flow-cytometry analysis of 
CXCR4+ cells was performed (see materials and methods). In accordance with qPCR 
results, all the analyzed MM cell lines express a significant decrease of cell surface CXCR4 
following GSI-XII treatment (fig. 3.2); in details a more dramatic reduction in CXCR4 at 
the cell surface was seen in KMS-12 and OPM-2 compared with that of RPMI-8226 cells. 
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Figure 3.2. Flow cytometry analysis of CXCR4 expression variation induced by GSI-XII. CXCR4 
surface expression was assessed after 48h of GSI-XII treatment. Reported values indicate the 
percentage of CXCR4+ cells and are representative of three independent experiments. 
 
 
Analogously, to confirm that the GSI-XII-mediated inhibition of SDF-1α mRNA 
expression also affected the levels of secreted chemokine, an ELISA assay was performed 
on conditioned medium of MM cells treated in the same conditions. 
The result of ELISA assay on SDF-1α showed in fig. 3.3, confirmed that Notch signaling 
inhibition also affected SDF-1α  secretion by MM cells (fig. 3.3) and, also in this case, a 
more relevant effect was evient in KMS-12 and OPM-2 compared with RPMI-8226 cell 
line. 
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Figure 3.3. GSI-XII  inhibits MM cell lines ability to secrete SDF-1α. Chemokine levels were 
measured by ELISA assay. Histograms represent the mean values of SDF-1α secretion of treated 
samples and control samples of one single experiment. Statistical analysis was performed using one-
tailed t-test and calculated on three independent experiments run in triplicate (**= P <0.01; ***= P 
<0.001).  
 
 
 
 
4. NOTCH PATHWAY INHIBITION HAMPERS CXCR4-DRIVEN 
CHEMOTAXIS 
 
Since our results showed that blocking the Notch pathway by γ-secretase inhibition caused 
a significant reduction in CXCR4 protein located at the cell surface, we hypothesized a 
possible functional effects of NOTCH pathway inhibition on CXCR4 biological function. 
I investigated whether GSI XII induced any changes concerning the ability of cell to 
migrate in response to its specific ligand SDF-1 (fig. 4.1). CXCR4-driven chemotaxis assay 
was performed on MM cell lines using Transwell polycarbonate filters supports with pore 
diameter of 8µm. 200.000 cells in the upper chamber were induced to migrate in response 
to 100 ng/ml SDF-1α added in the lower chamber.  
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Figure 4.1. Schematic representation of chemotaxis assay. Cell migration induced by SDF-1α 
chemokine was analyzed using a 8 µm pore diameter polycarbonate filter that was interposed 
between a top compartment in which MM cells were placed and a bottom compartment that contained 
the chemokine. 
 
 
Results show that GSI-XII mediated NOTCH pathway inhibition affects SDF-1α directed 
chemotaxis, inducing a decrease in the number of migrating MM cells ranging between 
30% and 45% (fig. 4.2). 
 
 
Figure 4.2. SDF-1α-driven chemotaxis assay of MM cell lines treated with GSI-XII. Graphs display 
the mean migration index (±SD) of three independent experiments run in triplicate. Statistical 
analysis was performed with two-tailed t-test. All observed variation are significant. Error bars 
represent ±S.D. 
 
Accordingly to qPCR and flow-cytometry results, RPMI-8226 cells displayed the lowest 
effect (30% reduction in mean MI). 
 
 
 
5. SDF-1α INDUCES A GROWTH INCREASE IN MM CELL LINES 
 
Since CXCR4 signaling is reported to exert a positive effect on cell proliferation, we 
wondered whether the GSI-XII-dependent reduced CXCR4 expression could be partially be 
involved in the anti-proliferative effects produced by Notch blockade in MM cells. The 
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presupposition that made this hypothesis reasonable was that CXCR4 signaling was active 
and had a proliferative otcome in the used MM cell lines. 
To test CXCR4 activation status in MM cells culture and to confirm the role of 
CXCR4/SDF-1 pathway in MM cell proliferation, the CXCR4/SDF-1 interaction was 
blocked in OPM-2 cells for 48 hours by the CXCR4 inhibitor AMD3100 or by SDF-1 
blocking antibody. 
The experiment was performed by treating OPM2 cells seeded at 700.000/ml with AMD-
3100 (at concentration of 1, 5, 10, 15 µM). After 48h cell viability was measured trough 
standard MTT assay (see material and method). 
The inhibition of the binding between SDF-1α and its receptor CXCR4, induced a decrease 
in cell viability suggesting that the CXCR4/SDF-1α pathway exerts a proliferative role in 
OPM2 cell growth (fig. 5.1).  
The obtained result was confirmed using a specific neutralizing antibody against SDF-1α 
(100 ng/ml) on OPM2 cell line plated in the same conditions. 
The result of the antibody-mediated neutralization of SDF-1α showed that blocking 
CXCR4 activation significantly reduced MM cell viability (fig. 5.2). 
 
Figure 5.1. Effect of AMD3100 on OPM2 cell growth.  Cells treated with AMD3100 1, 5, 10 and 
15µM for 48h were analyzed through an MTT assay performed as reported in materials and methods. 
Values reported in the graph represent the means +/-SD calculated on triplicate wells. Statistical 
analysis was performed by T-test: *** = P<0.001. The result is representative of three independent 
experiments. Cell= untreated cells. 
 
Figure 5.2. Effect of antibody neutralizing SDF-1α on OPM2 cell growth. Cells treated with 
100µg/ml anti-SDF-1α for 48h were analyzed through an MTT assay performed as reported in 
materials and methods. Values reported in the graph represent the means +/-SD calculated on 
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triplicate wells. Statistical analysis was performed by T-test: **= P<0.01. The result is representative 
of three independent experiments. Cell=untreated cells; Iso= cells treated with isotipyc Ab. 
 
These data indicated that CXCR4 signaling was active in MM cells in culture and induces a 
proliferative signaling. 
 
6. THE CXCR4/SDF-1 CHEMOKINE AXIS IS A PROLIFERATIVE 
EFFECTOR DOWNSTREAM THE NOTCH PATHWAY 
 
Previous findings indicating that both NOTCH and CXCR4 signaling may induce 
proliferation and that CXCR4 is regulated by NOTCH pathway made us hypothesize that 
CXCR4 could be a downstream effector of NOTCH in the proliferative signaling. 
According to this hypothesis, GSI-XII-mediated inhibition of cell proliferation could be 
rescued by up-regulating the signaling of residual CXCR4 obtained by the exogenous 
administration of SDF-1α. 
MM cells were treated with 6 µM GSI-XII or 0.5 µg/mL SDF-1α or simultaneously with 
the two compounds for 48h to check whether SDF-1 administration could limit the anti-
proliferative effect of GSI-XII. Viable cells excluding Trypan Blue vital dye were counted 
with Burker-type chamber. 
Hyper-stimulation of CXCR4, obtained by the addition of a high amount of chemokine in 
the culture medium was able to partially reverse the effect of inhibition of cell proliferation 
induced by the drug (fig. 6.1). 
 
 
Figure 6.1. CXCR4/SDF-1 system mediates Notch proliferative effect on MM cell lines. Combined 
treatment with 6 µM GSI-XII and 100 ng/ml SDF-1α was performed on MM cell lines for 48 hours. 
The mean cell number ± S.D of three experiments is displayed. Statistical analysis was performed by 
ANOVA and Tukey post-test: # = P> 0.05 (non significant). The comparison between all the other 
cell populations resulted significant. C= control; G/S = GSI-XII + SDF-1α. 
 
These data indicate that CXCR4 can be a proliferative effector downstream Notch pathway.  
Furthermore, we observed that the proliferative effect observed in OPM-2 cells following 
SDF-1α administration can be reduced by GSI-XII-mediated Notch withdrawal. These 
results suggest that it could be possible to antagonize the possible positive effect of SDF-1α 
in cell growth by targeting the Notch pathway.  
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The amount of DNA was also analyzed on treated cells by PI staining and flow cytometry 
to assess whether the reported effects were mediated by a regulation of the cell cycle 
progression. 
SDF-1 administration completely rescued GSI-XII-dependent cell cycle arrest in the G2/M 
phase resulting in G0/G1 phase increase (fig. 6.2). 
 
Figure 6.2. Cell cycle analysis of OPM-2 co- treated with GSI-XII and SDF-1α. DNA content was 
measured after a 48h treatment. Values indicate the percentage of cells in each phase of cell cycle in 
one experiment representative of three independent experiments. C= control; G= GSI XII; S= SDF-1 
α ; G/S = GSI-XII + SDF-1α. 
 
Finally, the ability of SDF-1α to rescue GSI-XII mediated apoptosis was tested. Increasing 
SDF-1α level is able to prevent apoptosis occurring after GSI-XII treatment (fig. 6.3). 
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Figure 6.3. Apoptosis assay of OPM-2 treated with GSI-XII and/or SDF-1α. Values represent the 
percentage of cells in early (Ann+/PI-) or late (Ann+/PI+) apoptosis in one experiment representative 
of three independent experiments. C= control; G= GSI XII; S= SDF-1 α ; G/S = GSI-XII + SDF-1α. 
 
 
In conclusion these sets of data suggest that the autonomous loop of Notch-mediated 
activation of CXCR4 signaling in MM cells can be effective in sustaining cell proliferation 
and resistance to apoptotic stimuli. 
 
7. NOTCH1 OVEREXPRESSION INCREASES CXCR4 PROTEIN 
LEVEL ON SURFACE OF OPM2 CELL LINE 
 
To further confirm the results concerning Notch-dependent regulation of CXCR4 obtained 
by GSIXII-mediated Notch inhibition and to obtain information on the specific role of the 
Notch1 isoform, we used an opposite and specific approach addressed to selectively 
upregulate Notch1.  
At this purpose we analyzed the outcome of the forced expression of the oncogene Notch1 
in OPM2 cells. 
OPM-2 cells were transiently transfected with plasmids pcDNA3-Notch∆E (see material 
and method), containing the intracellular region of Notch1 which represents the oncogenic 
constitutively active portion of the gene; the empty vector pcDNA3 was used as negative 
control. 
Cells were analyzed by flow-cytometry 48 hours later. ∆E-N1 increased the frequency of 
CXCR4+ cells by 25% compared with empty pcDNA3.1 (mock) (fig. 7.1). 
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Successful forced Notch1 activation was confirmed by flow-cytometry measurement of 
active Notch1 levels: ∆E-N1 increased the frequency of active Notch1+ cells by over 2 
times compared with mock vector (fig. 7.2).  
 
To confirm that the increase of CXCR4 expression after pcDNA3-Notch∆E transfection 
was induced specificly by Notch, 3 µM GSI-XII was added to the medium of MM cells 24 
h after transfection and 24 h before the collection.  
Since the Notch1 fragment carried by pcDNA3-Notch∆E still contains the transmembrane 
region of Notch, the resulting Notch protein fragment still needs to be cleaved by γ-
secretase, therefore being sensible to GSI-XII.  
Collected cells were analyzed by flow cytometry to analyze CXCR4 surface expression. 
OPM2 cells transfected with pcDNA3-∆E significantly increase CXCR4 expression level 
on cell surface; moreover GSI-XII is able to prevent the effect of Notch∆E on CXCR4 
expression confirming that Notch specifically regulates CXCR4 protein expression (fig. 
7.1). 
Successful inhibition of Notch1 activation was confirmed by flow-cytometry measurement 
of active Notch1 levels: 3µM GSI-XII is able to abrogate the level of Notch1 activity 
referable to both pcDNA3-Notch∆E and endogenous Notch1(fig. 7.2). 
 
Figure 7.1. Flow cytometry analysis of CXCR4 cells following the forced expression of the active 
Notch1 in the presence or in the absence of 3 µM GSI-XII. The values showed in the figure are the 
mean +/-SD calculated on two independent experiments. 
 
Figure 7.2. Flow cytometry analysis of Notch activation following OPM-2 electroporation with 
pcDNA-Notch∆E in presence or in absence of 3 µM GSI-XII. The values indicate the percentage of 
cells positive for active Notch1 and are the mean +/-SD calculated on two independent experiments. 
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8. JAGGED 1-2 SILENCING REGULATES MM CELL LINES 
PROLIFERATION AND APOPTOSIS 
 
Although GSI-XII is a potent inhibitor of the Notch pathway, it acts indirectly by 
preventing the γ-Secretase activity. In addition, this enzyme has about 50 substrates among 
type I membrane proteins, including ErbB-4 (Lee, 2002), E-cadherin (Marambaud, 2002), 
Colony Stimulating factor-1 (Wilhelmsen, 2004) and Interleukin-1 Receptor II (Kuhn, 
2007). Therefore, to confirm the selective contribution of Notch pathway to CXCR4 
expression, a different and more specific approach was used. 
The inhibition of the NOTCH pathway was obtained trough Jagged1 and 2 (JAG1-2) 
specific knock-down (see material and method) (fig. 8.1). As reported, these two genes are 
reported to present or upregulated in MM, resulting in Notch pathway activation. All the 
cell line in analysis express both Jagged1 and Jagged2 (data not shown). 
 
 
Figure 8.1. Schematic representation of Jagged1-2 siRNA assay. 
 
OPM-2 cells were seeded at 350.000 cells/ml and after 24h Jagged1 and 2 genes were 
simultaneously silenced in OPM-2 MM cell line using stealth siRNA transfection; cells 
treated with scrambled siRNA were used as negative control; cells treated with fluorescent 
scrambled sdRNA were used as positive control of transfection (fig. 8.2). Every 48h cell 
were diluted and treated again with JAG1-2 siRNA up to 8 days. At  each time-point, cells 
were collected and analyzed to test their proliferation, cell cycle and apoptosis status. 
Effectiveness of JAG1-2 silencing was assessed by quantitative PCR. As shown in figure 
8.3, Jagged 1 and Jagged2 expression was greatly reduced, as well as the expression of the 
Notch transcriptional target-gene Hes1. The selectiveness  of Notch ligands knock-down 
was shown through the lack of effect on Notch1 and 2 expression (fig. 8.3). 
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Figure 8.2.  Flow cytometry analysis of OPM-2 cells transfected with the “BLOCK-IT” fluorescent 
sdRNA from 6 to 170h. Values represent the percentage of cells BLOCK-IT+. The transfection 
successfully occurred and was detectable already at 6h time point. 
 
 
Figure 8.3. Quantitative PCR on 96h Jagge1/2-silenced OPM-2 cell line. OPM-2 cells were 
transiently transfected with 25 nM anti-Jagged1 and 25 nM anti-Jagged2 siRNAs, or equal amounts 
of scrambled siRNAs as negative controls. Jagged1 and Jagged2 silencing was assessed by 
quantitative PCR compared to scrambled siRNA-transfected cells. Gene expression variations were 
evaluated comparing si RNA treated cells to scramble treated controls using the 2-∆∆Ct method. 
Histograms represent mean ± SD and were calculated on three independent experiments run in 
triplicate. The fold change of genes was normalized on GAPDH housekeeping gene expression levels. 
 
The analysis of cell proliferation was made through the count of viable cells excluding 
Trypan Blue vital dye with Burker-type chamber. Notch pathway inhibition trough JAG1-2 
siRNA had a negative effect on cell growth compared with scrambled (fig. 8.4). 
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Figure 8.4. Effect of JAG1-2 siRNA on OPM2 cell proliferation. Cells treated with 50nM JAG1-2 
siRNA were counted and treated again every 48h up to 8 days. Values reported in the graph represent 
the mean value of triplicate wells. Statistical analysis was performed by T-test: **= P<0.01; *** = 
P<0.001. The comparison between all the cell populations resulted significant. The experiment was 
repeated two times with equivalent results. SCR=scrambled; J1+J2= JAG 1-2 siRNA. 
 
 
Cell cycle analysis on JAG-silenced MM cell line was performed as reported above. 
Differently from that reported for GSI-XII treatment, in this case cell cycle distribution 
analysis revealed that JAG1-2 silencing did not significantly affect cell cycle compared to 
scrambled sample (fig. 8.5). This result make us hypothesized, according to studies 
previously described (Rasul et al., 2009), that the GSIXII-mediated cell cycle blockade 
could be an effect of γ-secretase inhibition in MM cell lines independent from Notch 
withdrawal. 
 
Figure 8.5. Cell cycle analysis of OPM-2 after the treatment with JAG1-2 siRNA. DNA content was 
measured after 96h of treatment. Values indicate the percentage of cells in each phase of cell cycle in 
one experiment representative of three independent experiments. 
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The effect of JAG1-2 inhibition on MM cell lines apoptosis was investigated. Apoptosis 
assay was performed trough the Annexin-IV/PI double staining method analyzing positive 
cells by flow-cytometry. JAG1-2 silencing resulted in the increase of Annexin-V+ cells by 
30-40% on average (fig. 8.6), confirming the result obtained by Notch inhibition GSI-XII-
mediated. 
 
 
Figure 8.6. Apoptosis assay of OPM-2 after the treatment with Jagged1-2 siRNA. Values represent 
the percentage of cells in apoptosis in one experiment representative of three independent 
experiments. The figure shows that the level of Jagged1-2 siRNA-induced apoptosis was significant 
(p=0.001) only after 4 days treatment. Statistical analysis was performed by T-test: #=P>0.05; **= 
P<0.01; *** = P<0.001.The figure shows one experiment representative of three independent 
experiments. SCR= scrambled; J1+J2= Jagged1-2 siRNA. 
 
9. JAGGED 1-2 SILENCING HAMPERS CXCR4/SDF-1 
EXPRESSION IN MM CELL LINE  
 
The effects of JAG1-2 silencing on the expression of CXCR4 and its ligand SDF-1 were 
analyzed in OPM-2 MM cell line. Cells were treated as previously reported and quantitative 
PCR was performed to evaluate variations in HES-1, CXCR4 and SDF-1 mRNA levels. 
The treatment significantly reduced the levels of HES-1 mRNA indicating that the Notch 
pathway was effectively inhibited; JAG1-2  inhibition correlated with CXCR4 and SDF-1 
down-regulation (fig. 9.1).  
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Figure 9.1. Quantitative PCR on 96h Jagge1-2-silenced OPM-2 cell line. CXCR4/SDF-1 expression 
level in Jagged1-2 silenced cells was assessed by quantitative PCR compared to their expression level 
in scrambled siRNA treated cells. Gene expression variations were evaluated comparing siRNA 
treated cells to scrambled treated controls using the 2-∆∆Ct method. The fold change of genes was 
normalized on expression levels of housekeeping gene GAPDH. The values showed in the figure are 
the mean +/-SD calculated on one experiment run in triplicate, representative of three experiments. 
 
 
 
The CXCR4 reduction at protein level was confirmed trough flow-cytometry analysis: 
JAG1-2  inhibition produced a down-regulation of CXCR4+ cells compared with scrambled 
(fig. 9.2), analogously to the effect of Notch withdrawal induced by GSI-XII. 
 
 
 
Figure 9.2. Flow cytometry analysis of CXCR4 expression variation induced in OPM-2 cells by 
Jagged1-2 silencing. CXCR4 surface expression was assessed after 96h of Jagged1-2 siRNA. The 
values indicate the percentage of CXCR4+ cells and are representative of three independent 
experiments. 
 
 
The SDF-1 reduction at protein level was confirmed trough flow-cytometry analysis: 
JAG1-2  inhibition produced a down-regulation of SDF-1+ cells compared with scrambled 
(fig. 9.3). 
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Figure 9.3. Flow cytometry analysis of SDF-1 expression variation induced in OPM-2 cells by 
Jagged1-2 siRNA. SDF-1 intracellular expression was assessed after 96h of Jagged1-2 siRNA. The 
values indicate the percentage of SDF-1+ cells and are representative of three independent 
experiments. 
 
 
10. MM CELLS STIMULATE THE PRODUCTION OF 
SUPPORTIVE SOLUBLE FACTORS BY TRIGGERING THE 
NOTCH SIGNALING IN BMSCS  
 
Malignant plasma cells establish an intimate relationship with the bone marrow 
microenvironment, where tumor cells are supported by specialized niche that sustains their 
growth (Palumbo, 2011). Indeed, positive feedback loops are active between MM cells and 
stromal cells, osteoclasts, osteoblasts and vascular elements. These not only support the 
growth of the myeloma clone but also mediate drug resistance. To evaluate whether Notch 
deregulation in MM cells plays a role in their interaction with stromal cells, I designed in 
vitro co-culture assays affording Notch pathway modulation, to better understand the 
mechanism of cross-talk between these two cell population. The murine fibroblast NIH-3T3 
cell line as a model of Bone Marrow Stromal Cells (BMSCs) was chosen. 
As first step, to characterize the NIH3T3 cells regarding Notch pathway expression and 
activation, I began to evaluate the presence of the Notch family members (Notch1 to 4), 
their ligands (Jagged 1,2) and Hes1 target gene in NIH-3T3 cells through PCR analysis. All 
genes examined were detectable in NIH-3T3 cell line (fig. 10.1). 
 
 
Figure 10.1. PCR indicating the expression of Notch1-2, Jagged1-2 ligands and Hes1 genes in 
NIH-3T3 cell line. 
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This analysis indicated that all 4 Notch receptors and 2 ligands were expressed and 
consequently potentially able to trigger Notch signaling.    
To investigate whether Notch pathway was active, NIH-3T3, cells were seeded at 
300.000/ml and treated with 6µM GSI-XII or vehicle for 48h. The expression level of Hes1 
gene was evaluated as indicative GSI-XII inhibiting treatment. The result (fig. 10.2) shows 
that no reduction of HES1 mRNA level indicating that the Notch pathway was not active in 
NIH-3T3 cell line. 
 
 
Figure 10.2. Quantitative PCR on 48h GSI XII treated NIH-3T3 cell line. Notch, Jagged and Hes1 
gene expression levels were assessed by quantitative PCR compared to their expression level in 
DMSO treated cells. The fold change of genes was normalized on GAPDH housekeeping gene 
expression levels. The values showed in the figure are the means +/-SD calculated on one experiment 
run in triplicate, representative of three experiments. N1= Notch1; N2= Notch2; J1= Jagged1; J2= 
Jagged2; H1=Hes1. 
 
Since BMSCs are reported to sustain the proliferation of malignant plasma cells with 
potential contributions of both physical adhesion and soluble factors, I wondered whether in 
my system,  OPM-2 cells may induce the secretion of soluble supportive factors from NIH-
3T3 cells. In addition, I also investigated if stromal cells were able to promote the MM 
cells-mediated production of factors relevant in MM progression. 
Since Notch pathway was not deregulated in 3T3 cell line (as was shown in previous 
result), we hypothesized that BMSC could activate Notch signaling only trough direct 
stimulation from malignant plasma cells contact, thus becoming supportive for MM cells 
trough up-regulation and production of soluble an survival factor. 
To verify this purpose co-culture assay was used: OPM-2 MM cell line was plated on a 
monolayer of NIH-3T3 cells at 1:1 ratio (see material and method). Cells in single-culture 
were used as control. After 48h cells were processed for qPCR analysis to test the gene 
expression levels of soluble factors, relevant in MM. In the analysis we were able to 
discriminate between transcripts from OPM-2 or NIH3T3 cells by using respectively 
human or murine specific primers. 
Fig. 10.3 shows that the presence of NIH3T3 cells induces in OPM-2 cells a variable  
upregulation of SDF-1, RANTES, RANKL and IL-6 genes in comparison to the  
expression in OPM-2 cells alone (IL-6 gene less then other). 
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The expression of MIP-1α gene was down-regulated compared to its expression in single 
culture. 
CXCR4 and VEGF genes were not affected. 
Hes1 in OPM-2 cells was not affected by the contact with NIH3T3 cells, indicating that 
Notch pathway was not up-regulated by BMSC contact. 
 
Figure 10.3. Quantitative PCR on the expression of soluble factors and CXCR4 genes in 48h co-
cultured OPM-2/NIH-3T3 cells. Gene expression variations were evaluated comparing OPM-2 co-
cultured cells to OPM-2 in single culture using the 2-∆∆Ct method. The fold change of genes was 
normalized on the expression levels of the housekeeping gene, GAPDH. The values showed in the 
figure are the means +/-SD calculated on one experiment run in triplicate, representative of three 
experiments. 
 
On the other side, fig. 10.4 displays that NIH-3T3 cells are induced by the presence of 
OPM-2 to upregulate the expression of SDF-1, CXCR4, IL-6, VEGF, RANTES, MIP-1α 
genes. The expression of RANKL gene had no variations compared to its expression in 
single culture. 
Hes1 expression also was up-regulated in co-culture compared with its expression in single 
culture, indicating that Notch pathway was activated in NIH-3T3 cells by contact with MM 
cells. 
 
Figure 10.4. Quantitative PCR on the expression of soluble factors and CXCR4 genes in 48h co-
cultured OPM-2/NIH-3T3 cells. Gene expression variations were evaluated comparing NIH-3T3 co-
cultured cells to NIH-3T3 in single culture using the 2-∆∆Ct method. The fold change of genes was 
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normalized on the expression levels of the housekeeping gene, GAPDH. The values showed in the 
figure are the means +/-SD calculated on one experiment run in triplicate, representative of three 
experiments. 
 
All these results indicate that MM cells are able to trigger Notch signaling in NIH-3T3 cells 
and the release of soluble factors which sustain MM cell  progression. 
By contrast these results do not support the possibility that BMSCs activate the Notch 
pathway in MM cells, supporting the possibility that  Notch signalling activation is 
thoroughly due to the expression of the two Notch ligands Jagged1 and 2.  From this 
evidence stems the consideration that the observed upregulation in the expression of SDF1, 
RANKL and RANTES is OPM-2 cell is autonomous and not due to the presence of NIH-
3T3 cells.  
 
Finally, to clarify which is the Notch contribute in this cross-talk and to investigate whether 
the Jagged ligands expressed by MM cells are able to trigger the Notch signaling in 
BMSCs, I designed a co-culture assay in which NIH-3T3 cells were in contact with OPM-2 
cells depleted or not of Jagge1 and 2. 
To selectively inhibit MM-jagged, it was used siRNA approach. 
OPM-2 cells were seeded at 300.000 cells/ml and after 24h the JAG1-2 siRNA treatment 
was added. After 48h cells were diluted and treated once again with silencing treatment. 
After 8h OPM-2 cells were washed and finally plated on a monolayer of NIH-3T3 cells at 
1:1 ratio (see material and method). Co-cultures were manteined for 48h, obtaining in this 
way a condition in wich MM cells were silenced from 4 days (since a 48h silencing was not 
sufficient to induce a great response in MM cells). Cells treated with scrambled siRNA 
were used as negative control. 
The results in fig. 10.6 show that when NIH-3T3 cell line are placed in co-culture with 
OPM-2 treated with JAG1-2 siRNA, the expression of all tested genes was down-regulated 
if compared to the same expression in NIH-3T3 cells co-cultured with control OPM-2 cells 
(treatment with scrambled siRNA). The parallel strong down regulation of Hes1 expression, 
indicated that Jagged-expressing MM cells trigger the Notch pathway in NIH-3T3, which in 
turn produce soluble factors. In fact, when the Jagged ligands are turned-off in MM cells, 
NIH-3T3 cells are no more able to produce soluble factors fundamental for MM 
progression. 
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Figure 10.5. Quantitative PCR on the expression of soluble factors and CXCR4 genes in 48h NIH-
3T3 co-cultured with Jagged1-2 silenced OPM-2. Gene expression levels in NIH-3T3 co-cultured 
with silenced OPM-2 were assessed by quantitative PCR compared to their expression levels in NIH-
3T3 co-cultured with non-silenced OPM-2. The fold change of genes was normalized on GAPDH 
housekeeping gene expression levels. The figure shows the “reduction index” which indicate the 
reduction percentage of gene expression compared with the genhe expression leves showed in figure 
10.4. The values showed in the figure are representative of three independent experiments. 
 
 
Overall these results shows that the production of soluble factors by BMSC occurs only 
when Notch pathway in MM is active, in particular when Jagged1-2 expressed on MM cell 
bind the Notch receptor on BMSC surface. 
In conclusion, these results are consistent with the possibility that upregulated Jagged 
ligands in MM cells are responsible of deregulated Notch signaling in BMSC, resulting in 
the secretion of soluble factors promoting MM progression.   
 
11. JAGGED 1 AND 2 INDUCE IN MM CELLS INTRINSIC 
SURVIVAL MECHANISM WHICH IS NOT DEPENDENT BY BMSC 
 
The above reported results represent a rationale for blocking of Jagged ligands as a 
therapeutic approach to disrupt the pathological interaction of MM cells with BMSCs. 
In literature is largely known that stroma in BM of MM patiens is able to support MM cells, 
inducing survival from apoptosis and drug resistance (Hideshima, 2002a). 
Indeed if BMSCs were able to save MM cells from apoptosis induced by Jagged blockade 
(previously reported in fig. 8.5), any Jagged tailored therapeutic approach would be 
ineffective.  
To address this issue, I investigated whether BMSCs would influence the apoptotic 
response of myeloma cells to the inhibition of Jagged1 and 2. 
OPM-2 cells were treated with JAG1-2 siRNA and co-cultured as previously reported 
(10.2). 
The result in figure 11.1 shows that the stromal layer of NIH-3T3 is not able to revert the 
apoptosis induced by Jagged withdrawal, confirming the hypothesis that the surviving loop 
occurring between MM and BMSC cells is induced by upstream MM-jagged signaling and 
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that pathological interaction between MM cells and BMSCs needed a Notch active pathway 
and therefore it is interrupted by Jagged depletion in MM cells (fig.11.1). 
 
 
Figure 11.1. Apoptosis assay of OPM-2 co-cultured or not within-3T3 and after the treatment with 
Jagged1-2 siRNA. The apoptosis percentage of Jagged1-2 silenced OPM-2 in single culture was 
compared to that of Jagged1-2 silenced OPM-2 co-cultured with NIH-3T3: the variation was not 
significative (indicated with symbol #). The mean of apoptosis value ± S.D of three experiments was 
displayed. Statistical analysis was performed by ANOVA test: **= P<0.01 (significant); # = P> 0.05 
(non significant). The comparison between all the other cell populations resulted significant. SCR= 
scrambled; J1+J2= Jagged1-2 siRNA. 
 
In conclusion, deregulated Jagged activity in MM cells is the “condicio sine qua non” to 
initiate the survival loop that occurs between malignant plasma cell and BMSC. 
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DISCUSSION 
 
 
Multiple myeloma (MM) is a neoplastic plasma cell disorder that results in end-organ 
damage: beyond hypercalcemia, renal insufficiency and anemia, the most important injury 
associated to negative prognosis is represented by skeletal lesions (Kyle, 2009).  
Bone destruction is due to MM cells localization at the bone marrow due to chemokine 
system deregulation. Malignant plasma cells migrated at the bone marrow interact with 
bone marrow stromal cells (BMSC) through direct cell-cell contact and secretion of soluble 
mediators, activating several pathways which bring to osteoclasts (OCL) activation and 
bone resorption.  
MM therapy is rarely curative, and a median survival is about 3-4 years after diagnosis 
which may increase to 5–7 years or more with advanced treatments (Kyle, 2004). The 
treatment of MM is complex and it exploits different approaches, including: 
• Chemotherapy; 
• Bone marrow stem cell transplantation (autologus or allogenic); 
• Immune modulating treatments such as thalidomide (Thalomid®), 
lenalidomide (Revlimid®), and bortezomib (Velcade®); 
• Corticosteroids (such as prednisone or dexamethasone) treatment. 
Initial chemotherapy for patients with symptomatic MM depends on the possibility to 
perform  autologous stem cell transplantation (ASCT), which depends from age, 
performance status, and the presence of comorbid conditions in the patients. Patients who 
are ineligible for ASCT are submitted to initial chemotherapies. Currently, the preferred 
therapy is Melphalan/Prednisone/Thalidomide for the treatment of standard-risk myeloma 
patients, whereas Bortezomib/Melphalan/Prednisone is recommended for patients with 
high-risk disease (Kyle, 2009). 
Although associated to side effects, treatments with thalidomide, lenalidomide, and 
bortezomib represent a therapeutic advance in MM therapy, nevertheless, almost all 
patients systematically relapse, and therefore MM remains an incurable disease (Kumar, 
2009). Therefore, the need of novel drug targets and therapeutic strategies to selectively 
target molecules relevant in MM cell progression and pharmacological resistance is 
evident. In the last years several studies were address to find rational molecular targets for 
cancer treatment, in order to develop target-selective “smart” drugs, on the basis of 
characterized mechanisms of action (Miele, 2006).  
Recently, Podar et al. (2009) described the possibility to develop an innovative therapy 
aiming at the inhibition of  pathways activated in MM (i.e. Notch/JAG, PI3K/Akt, 
JAK/Stat, Raf/MEK/MAPK, NFκB and Wnt) which regulate cell proliferation, survival, 
migration and drug resistance.  
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The inhibition of the Notch pathway represents a new target-based therapy for those tumors 
characterized by Notch activation. From 1990s to present, Notch signaling aberrations have 
been shown to be linked with several hematological malignancies, such as T-cell acute 
lymphoblastic leukemia (T-ALL), acute myeloid leukemia (AML), lymphoma and MM 
(Mirandola, 2011a). 
Deregulated Notch signaling has been reported not only to affect MM cell proliferation and 
apoptosis, but also to influence MM cell interaction with the BM milieu, resulting in 
increased resistance to chemotherapeutics and osteolysis (Nefedova, 2004; Schwarzer, 
2008). In MM, no mutations directly affecting Notch receptors or ligands are known, 
nonetheless Notch pathway deregulation seems to be a critical step in disease evolution. 
The expression of Notch1 and Jagged1 is deregulated upon disease progression from 
MGUS to MM (Skrtic, 2010). Furthermore, Jagged2 overexpression in MGUS and MM 
patients correlates with staging and it may induce IL-6, VEGF and IGF-1 production in a 
paracrine fashion (Houde, 2004). 
Jagged2 up-regulation may result from promoter demethylation (Houde, 2004), from 
constitutive core promoter acetylation associated to reduced levels of the SMRT co-
repressor (Ghosal, 2009) or at post-transcriptional level from aberrant expression of 
Jagged2 ubiquitin ligase skeletrophin (Takeuchi, 2005). 
The localization of MM cells in the bone marrow gives origin to several interactions with 
BMSCs. The outcome of Jagged2 upregulation in MM cells is the hyper-activation of 
Notch pathway in neighbouring healthy and tumor cells. These interactions activate several 
pathways which generate a vicious cycle, from which tumor cells take source for survival 
and proliferation. There is also evidence that Notch1 activation induces CCR6 expression in 
osteoclasts, promoting OCL recruitment to osteolysis sites and OCL activation; moreover, 
MM cell-BMSC interaction, induces abnormal expression of  RANKL by osteoblasts, 
which induces the maturation of OCL progenitors and subsequent bone resorption 
(Roodman, 2006). 
The above reported evidences on the role of Notch signaling in MM, suggests that Notch 
may be a rational specific target in MM therapy. 
The most diffused method to hamper Notch signaling is based on the inhibition of γ-
secretase, a membrane-integral protease complex, essential for Notch receptor activation. 
Although GSI’s efficacy in vitro has been demonstrated, in patients GSI displayed 
significant gastrointestinal toxicity and no clinical response in T-ALL. Gastrointestinal side 
effects have been studies in animal models, where chronic administration of GSIs boosted 
the formation of secretory globet cells in the intestine (Searfoss, 2003). Side effect in 
intestine is associated to Notch2 inhibition which is the consequence of the inability of GSI 
to distinguish between Notch proteins. 
At the moment, several phase I clinical trials were evaluated for the use of GSIs in clinical 
practice, such as  breast cancer, T-ALL and lymphoma, metasttic melanoma, colorectal and 
pancreatic adenocarcinoma; despite GSIs side effects, encouraging results suggest that 
Notch targeting trough γ-secretase inhibitors (GSIs), are potential novel cancer therapeutic 
agents. 
96 
 
This work aims to confirm that Notch signaling is a rational therapeutic target in MM and 
to identify a strategy of inhibition that avoid the above reported side effect.  
To confirm that the rational exists for a Notch tailored therapy,  I proceeded by steps: 
1) confirming the effects of Notch deregulation in MM cell lines. 
2) identifying other possible effects of Notch in MM progression different from those 
already described and involving the biology of tumor cells but also their interaction with 
stromal cells. 
3) investigating the underlying mechanisms involved.  
 
Notch inhibition negatively regulates MM cell proliferation  
Concerning the role of Notch in MM, it is generally acknowledged that Notch exerts an 
anti-apoptotic role in MM (Nefedova, 2008), by contrast, both proliferative (Nefedova, 
2008; Schwarzer, 2008; Jundt, 2004) and anti-proliferative (Nefedova 2004) roles of Notch 
have been reported. 
To confirm the effect of Notch deregulation in MM cell lines, I used several in vitro 
strategies to assess in vitro the molecular and biological effects of Notch inhibition.  
As first step, Notch pathway was inhibited by using GSI-XII in three different MM cell 
lines (OPM2, KMS-12, RPMI-8226). Treatment with GSI-XII displayed a negative effect 
on tumor cell growth, due to cell  cycle arrest in G2/M phase and contemporaneous 
decrease of cells in the S phase and to an apoptosis rate increase; these results are consistent 
with previous works indicating that NOTCH signaling deregulation promotes MM cell 
growth and inhibits apoptosis. 
 
The CXCR4/SDF-1 chemokine system is a down-stream Notch effector which 
regulates cell growth, proliferation and motility 
In order to identify other possible  effects of Notch in MM progression different from those 
already described in the literature, I further investigated other putative Notch downstream 
effectors. I focused my investigation on the possible cross-talk between Notch and  
chemokines system relevant for the pathogenesis of MM. Although my preliminary results 
indicated that Notch was able to regulate the transcription of CXCR4, CCR1 and CCR5 and 
all their ligands; a particular attention was given to the CXCR4/SDF-1 axis whose 
relevance in MM was shown by the evidence that it promotes MM cell localization at the 
BM and osteolytic lesions (Aggarwal, 2006; Diamond, 2009; Zannettino, 2005) and is 
associated with poor prognosis and disease progression in MM patients (Van de Broek, 
2006). 
In this study I found that Notch controlled the expression (both at transcriptional and 
protein levels) and function of both CXCR4 and SDF-1 in MM cells. The possible Notch-
mediated regulation of CXCR4/SDF-1 was investigated not only by inhibiting Notch 
signaling (through GSI-XII treatment), but also by forcing the expression of the 
constitutively active Notch Intracellular Domain (NICD). The forced expression of Notch1 
displayed an increased level of CXCR4 expression on cell surface and moreover in a 
specific Notch-mediated manner. This result confirmed that Notch pathway may control 
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CXCR4 expression levels and that, in particular, the Notch1 isoform plays this role. This 
does not exclude any possible role of the other Notch receptors. 
The relevance of these findings is evident when considering the role played by 
CXCR4/SDF-1 in MM progression. 
CXCR4/SDF-1 axis activates an important pathway involved in several features of tumor 
progression, including angiogenesis, metastasis and survival. In particular, in MM cells, 
SDF-1α triggers MAPK, PI3K/Akt and NF-κB, and promotes proliferation, migration, and 
protects against Dexamethasone-induced apoptosis (Hideshima, 2002). Within the bone 
marrow microenvironment, SDF-1 upregulates the secretion of IL-6 and VEGF in BMSCs, 
thereby promoting tumor cell growth (Hideshima, 2002). Also, Zannettino et al. (2005) 
demonstrated that the plasma level of SDF-1 correlated with the presence of lytic bone 
disease in MM patients, suggesting a potential role for SDF-1 in osteoclast precursor 
maturation and activation. Therefore Notch ability to control CXCR4 and SDF1 expression 
is a first indication  that it could affect further biological features of MM cells besides those 
already investigated. 
Indeed my subsequent work demonstrated that Notch was able to regulate biological effect 
mediated by CXCR4 signaling on MM cell lines. The negative effect of GSI-XII on MM 
cell viability  could be rescued by stimulating the residual CXCR4 receptor with exogenous 
administration of SDF-1α. I observed both a reversion of the G2/M blockage and apoptosis 
induced by GSI-XII treatment. On the whole, these results suggest that Notch favours the 
activation of an autonomous loop of stimulation mediated by the contemporary expression 
of CXCR4 and SDF-1 in MM cells. The activity of this chemokine axis is effective in 
sustaining cell growth by increasing cell proliferation and resistance to apoptotic stimuli, 
and GSI-XII-mediated Notch inhibition can uncouple it. 
My results also indicated that GSI-XII treatment antagonizes the proliferative effect 
associated to SDF-1 α mediated CXCR4 engagement.  
This observation futher confirms that Notch signalling can be a relevant therapeutic target 
in MM. Indeed the high amount of SDF-1 present in the BM are associated to high levels of 
CXCR4 signaling in MM cells, which therefore contribute to create a confortable niche 
further stimulating MM cells proliferation. The inhibition of Notch signalling could reduce 
the beneficial effect of SDF1 produced by BMSCs. 
Since chemotaxis is the better known function promoted by chemokines and SDF-1α is able 
to stimulate MM cell migration by engaging CXCR4, I also verified  if GSI-XII treatment 
was able to affect SDF-1α driven chemotaxis. My results indicating that Notch inhibition 
reduced MM cells migration suggest that Notch pathway is able to control SDF-1α-driven 
MM cell migration. In consideration that the axis CXCR4/SDF-1α is the  main responsible 
of MM localization at the bone marrow, these results strongly suggest that Notch pathway 
upregulation can positively regulate MM cells migration to the bone. This is a critical step 
in MM development and progression, necessary for pre-mailgnant plasma cells to 
accumulate mutations essential for their malignant transformation and for beginning the 
pathological interaction with BM stroma resulting in drug resistance and bone disease 
(Hideshima, 2002). 
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Jagged1-2 silencing regulates MM cell lines proliferation, apoptosis and CXCR4 
expression 
Since GSIs inhibit γ-secretase, whose activity is not exclusively involved in Notch 
receptors activation but also in the processing of different surface proteins (Kopan, 2004), a 
possibility exists that the observed biological outcomes of the treatment with GSI-XII are 
not exclusively related to the reduction of Notch activity. Therefore, data obtained with 
GSI-XII were also confirmed through a more specific approach. Due to the frequently 
observed deregulation of Jagged ligand reported in MM patients and to the high level of 
expression of the two ligands in the used cells lines, I induced Notch signaling inhibition by 
performing Jagged1 and 2 (JAG1-2) specific knock-down trough siRNA. This different 
inhibitory approach confirmed the previously obtained results  with the exception of 
changes in the cell cycle. The possibility to inhibit Notch signaling in MM by targeting the 
Notch ligands open important opportunities in the therapeutic approaches for MM. Indeed, 
as reported conventional approaches targeting Notch signaling based on non-selective 
inhibition of all Notch isoforms by GSIs result in severe goblet cell metaplasia and cause 
severe gastrointestinal toxicity. This problem could be circumvented by silencing the 
deregulated JAG ligands. In particular the early upregulation and the reported role of JAG2 
in MM, make it the most promising therapeutic target. 
 
Jagged1-2 expressed in MM cells are the elements upstream the MM/BMSC cross-talk 
A characteristic feature of myeloma cells is the requirement for an intimate relationship 
with the BM microenvironment, where specialized niches support plasma cells survival. 
Direct interactions between MM cells and BM cells are directly responsible for the failure 
of available therapies. The cross talk between MM cells and BM milieu activates signaling 
pathways that mediate growth, survival and migration of MM cells as well as 
osteoclastogenesis and cell-adhesion-mediated drug resistance (CAM-DR) (Damiano, 
1999). 
To better understand the mechanism of cross-talk between MM cells and BMSCs and to 
evaluate the role of Notch in this system, I investigated whether Notch activity in MM cells  
could influence the outcome of their interaction  with mouse NIH-3T3, fibroblasts used as 
surrogate of  BMSCs. JAG1-2 siRNA were used, to specifically inhibit Jagged1-2 
translation in MM cells co-cultured on a layer of  NIH-3T3 cells. 
The results indicate that The contact of the two cell lines induces up-regulation in MM cells 
of SDF-1, RANTES, RANKL and IL-6 soluble factors and that MM cells activate Notch 
signaling in NIH-3T3 cells by activity of Jagged ligands expressed in MM cells: Notch 
signaling activation in NIH-3T3 stromal cells is associated to the production from stromal 
cells of SDF-1, CXCR4, IL-6, VEGF, RANTES, MIP-1α soluble factors which in turn 
sustain MM cell proliferation, migration and drug resistance. The inhibition of Jagged1-2 
expressed on MM cells bind is associated to a decreased production of supportive soluble 
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factors by NIH-3T3 fibroblasts supporting the potential efficacy of a Jagged-tailored 
therapeutic approach in MM. 
The potential effectiveness of this approach is further confirmed by the evidence that  the 
stromal layer is not able to rescue from the apoptosis MM cells induced by Jagged 
withdrawal, confirming the hypothesis that the Notch/Jagged activity in MM cells is the 
upstream initiator of the surviving loop occurring between MM and BMSC cells. 
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CONCLUSIONS 
 
 
 
This thesis work shows that the Notch pathway has a key role in MM system since it is able 
to modulate MM cell proliferation, apoptosis and migration by deregulating the 
CXCR4/SDF-1 axis activity; in addition Notch seems to be essential for the pathologic 
cross-talk between MM cells and BMSCs critical for MM progression. 
 
The future perspective of this work could be to further extend information on the role of 
Notch in the pathological relationship between MM cells and the BM tumoral 
microenvironment, including  stromal cells osteoclasts, osteoblasts  and endotheial cells. 
 
Concluding, taken together, the results of this thesis if confirmed by clinical study on MM 
patients, could provide a rational for a therapeutic approach since both Notch and 
chemokine receptors are targeted by emerging drugs. Therefore, a Notch- and CXCR4- 
focused therapy could be exploited to significantly improve outcome and extend survival, 
by complementing conventional front-line treatments 
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